



Deposited via The University of Leeds.

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/id/eprint/116548/>

Version: Accepted Version

Article:

Moore, A, Ashdown, HF, Shinkins, B et al. (2017) Clinical characteristics of pertussis-associated cough in adults and children: a diagnostic systematic review and meta-analysis. *Chest*, 152 (2). pp. 353-367. ISSN: 0012-3692

<https://doi.org/10.1016/j.chest.2017.04.186>

© 2017 American College of Chest Physicians. Published by Elsevier Inc. This manuscript version is made available under the CC-BY-NC-ND 4.0 license
<http://creativecommons.org/licenses/by-nc-nd/4.0/>

Reuse

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.

Accepted Manuscript

Clinical characteristics of pertussis-associated cough in adults and children: a diagnostic systematic review and meta-analysis

Abigail Moore, BM BCh, Helen F. Ashdown, MRCP MRCGP, Bethany Shinkins, DPhil, Nia W. Roberts, MSc (Econ), Cameron C. Grant, PhD, Daniel S. Lasserson, MD, Anthony Harnden, FRCGP

PII: S0012-3692(17)30923-6

DOI: [10.1016/j.chest.2017.04.186](https://doi.org/10.1016/j.chest.2017.04.186)

Reference: CHEST 1109

To appear in: *CHEST*


Received Date: 28 February 2017

Revised Date: 11 April 2017

Accepted Date: 25 April 2017

Please cite this article as: Moore A, Ashdown HF, Shinkins B, Roberts NW, Grant CC, Lasserson DS, Harnden A, Clinical characteristics of pertussis-associated cough in adults and children: a diagnostic systematic review and meta-analysis, *CHEST* (2017), doi: 10.1016/j.chest.2017.04.186.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



Word count:

Text – 2628

Abstract – 249

Clinical characteristics of pertussis-associated cough in adults and children: a diagnostic systematic review and meta-analysis**Authors:**

Abigail Moore, BM BCh, University of Oxford
Helen F Ashdown, MRCP MRCGP, University of Oxford
Bethany Shinkins, DPhil, University of Leeds
Nia W Roberts, MSc (Econ), University of Oxford
Cameron C. Grant, PhD, University of Auckland
Daniel S Lasserson, MD, University of Oxford
Anthony Harnden, FRCGP, University of Oxford

Corresponding author:

Abigail Moore
Radcliffe Primary Care Building, Radcliffe Observatory Quarter, Woodstock Road, Oxford.
OX2 6GG
abigail.moore@phc.ox.ac.uk

Guarantor statement:

Abigail Moore takes responsibility for the content of the manuscript, including the data and analysis.

Author contributions:

All authors contributed substantially to the study design, data interpretation, and the writing of the manuscript.

NR designed the search strategy and ran and updated the searches.

AM and HFA screened the abstracts, completed full text reviews, data extraction and assessments of quality and bias. AH acted as an independent adjudicator for any discrepancies in this process.

BS completed the statistical analysis.

Conflicts of interest:

None to declare.

Funding information:

BS is funded by the National Institute for Health Research (NIHR) Leeds Diagnostic Evidence Co-operative.

DSL is funded by the NIHR Oxford Biomedical Research Centre.

The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the above centres, NIHR, NHS or the Department of Health.

Abstract

Background

Pertussis (whooping cough) is a highly infective cause of cough that causes significant morbidity and mortality. Existing case definitions include paroxysmal cough, whooping and post-tussive vomiting but diagnosis can be difficult. We determined the diagnostic accuracy of clinical characteristics of pertussis-associated cough.

Methods

We systematically searched CINAHL, Embase, Medline and SCI-EXPANDED/CPCI-S up to June 2016. Eligible studies compared clinical characteristics in those positive and negative for *Bordetella pertussis* infection, confirmed by laboratory investigations. Two authors independently completed screening, data extraction and quality and bias assessments. For each characteristic RevMan was used to produce descriptive forest plots. We used the bivariate meta-analysis method to generate pooled estimates of sensitivity and specificity.

Results

Of 1969 identified papers, 53 were included. Forty-one clinical characteristics were assessed for diagnostic accuracy. In adult patients, paroxysmal cough and absence of fever had a high sensitivity (93.2%, CI 83.2-97.4 and 81.8%, CI 72.2-88.7 respectively) and low specificity (20.6%, CI 14.7-28.1 and 18.8%, CI 8.1-37.9 respectively), whereas post-tussive vomiting and whooping had low sensitivity (32.5%, CI 24.5-41.6 and 29.8%, CI 8.0-45.2 respectively) and high specificity (77.7%, CI 73.1-81.7 and 79.5%, CI 69.4-86.9 respectively). Post-tussive vomiting in children is moderately sensitive (60.0%, CI 40.3-77.0) and specific 66.0%, CI 52.5-77.3).

Conclusions

In adult patients the presence of whooping or post-tussive vomiting should rule in a possible diagnosis of pertussis, whereas the lack of a paroxysmal cough or the presence of fever should rule it out. In children, post-tussive vomiting is much less helpful as a clinical diagnostic test.

Introduction

Pertussis (whooping cough), caused by *Bordetella pertussis* infection, is a prevalent cause of acute cough that can often become persistent in both children and adults presenting to primary care and other health care settings.^{1,2} Pertussis remains an important cause of child mortality, with an estimated 195,000 deaths reported globally in 2008.³ In older age groups pertussis causes significant morbidity and generates substantial costs and work absence.⁴ Neither natural infection nor immunisation result in life-long immunity.⁵

The symptom triad of paroxysmal cough, whooping and post-tussive vomiting are classically considered essential clinical characteristics, and the Center for Disease Control (CDC) and World Health Organization (WHO) clinical case definitions reflect this.^{6,7} However, in clinical practice pertussis-associated cough can occur anywhere along a clinical severity spectrum from minor cough to repeated severe paroxysms.^{8,9} Previous immunisation or infection can attenuate the symptoms, especially cough, that occur with a subsequent *B. pertussis* infection.¹⁰ The disease frequently also presents atypically in young infants.^{11,12}

Laboratory confirmation of *B. pertussis* infection can be performed using culture (100% specific), polymerase chain reaction (PCR) (88-100% specific), or serology (72-100% specific).^{13,14} However, a practising clinician who needs to make an urgent patient management decision frequently has to do this without laboratory data. Identifying pertussis as the cause of a clinical presentation of cough illness is important because of the high infectivity of *B. pertussis*,⁸ its significant morbidity and the potential for complications and death, particularly in young infants.¹⁵ Offering a secure clinical diagnosis also helps prevent unnecessary investigations, inappropriate antibiotics and offers patients a more accurate cough prognosis. Early recognition and treatment may also prevent spread of the disease.

Although the diagnostic accuracy for pertussis of different symptoms and signs has been tested in multiple clinical studies, they have not previously been combined in a comprehensive systematic review. A better understanding of the clinical characteristics of pertussis-associated cough, and other clinical features could help clinicians differentiate pertussis cough from other causes of cough.

We therefore aimed to conduct a systematic review and meta-analysis to determine the diagnostic accuracy of clinical characteristics of pertussis-associated cough.

Materials and methods

Study selection and data extraction

A diagnostic test accuracy protocol was developed using the relevant Cochrane handbook¹⁶ but not formally registered (available on request). We considered as eligible studies which included patients of any age attending any health care setting, including pertussis outbreaks, with any clinical characteristic (index test) which might be associated with pertussis, compared to laboratory confirmation of *B. pertussis* (reference standard). We included all studies with sufficient published or unpublished data to construct 2x2 tables for each clinical characteristic(s). Studies were excluded if pertussis diagnosis was not confirmed with recognised laboratory methods (culture, PCR or serology) or there was no suitable comparison group. Studies looking at *B. parapertussis* only were also excluded. By design our inclusion criteria were broad in order to capture the full spectrum of pertussis presentation.

We systematically searched databases CINAHL(EBSCOHost, 1982-present], Embase (OvidSP, 1974-2016 June 02), Medline & Medline In-Process (OvidSP, 1946-present) and SCI-EXPANDED/CPCI-S(Web of Science Core Collection, 1945-present) from inception to November 2014, and this was then updated in June 2016. The search strategy combined MeSH headings with free text search terms for whooping cough and clinical symptoms. English language restrictions were applied. Results were supplemented by review of reference lists of included articles and relevant review articles. e-Appendix 1 gives the full search strategy used for CINAHL as an example.

Titles and abstracts were screened to exclude any obviously irrelevant articles. Full texts of potentially relevant articles were then assessed for eligibility. All steps were completed in tandem by two authors (HFA and AM), with any discrepancies discussed and, if necessary, resolved by adjudication with a third author (AH). We contacted authors of studies to request additional data relevant to this review where it was apparent that it was likely to have been collected but not published. Authors were contacted by email, with a reminder sent at 2 weeks and 4 weeks if no response. We developed and piloted a standardised data extraction form, which was revised until it captured all relevant information. This data extraction form was sent to facilitate return of data in a useable format.

Data extraction and risk of bias assessment were subsequently carried out in duplicate and independently by HFA and AM. Risk of bias was assessed using the QUADAS-2 tool in the domains of patient selection, index tests, reference standard and flow and timing.¹⁷ Completed data extraction forms were compared and any discrepancies checked and resolved. We extracted information on study characteristics, design, details of the reference test used for pertussis detection, the characteristics of included patients and information on

missing data. For each clinical characteristic described, data for a 2x2 table were extracted or calculated from the data presented. Data were entered into a Microsoft Excel spreadsheet by one author (AM) and checked by a second (HFA). Terms used to describe clinical characteristics varied slightly across studies. Similar characteristics were grouped together using clinical judgement by one author (HFA) and checked by a second (AM).

Statistical analysis

Statistical analysis was completed by BS. Binary diagnostic accuracy data were extracted from all included studies as 2x2 tables. For each clinical characteristic, RevMan was used to produce descriptive forest plots to explore the between-study variability in sensitivity and specificity across the included studies. ROC plots were produced, sub-grouped by age of included participants (children, adults or both). The size of each study point is scaled to be proportional to the inverse standard error of the study sensitivity and specificity.

Where sufficient data were available (minimum of four studies), we used the bivariate meta-analysis method to generate pooled estimates of sensitivity and specificity, along with 95% confidence and prediction regions. Results were only pooled within each age-range of patient, categorised as either children or adults. Studies with both adults and children were not included as the presentation of the disease in the age groups are not the same.¹¹ Due to high heterogeneity, we excluded from meta-analyses studies at high risk of bias on any of the four QUADAS-2 domains, which was a pre-specified sensitivity analysis. In cases where notable heterogeneity remained, meta-analysis was deemed inappropriate.

We planned additional sub-group analyses to explore other possible causes of heterogeneity (co-morbidity, immunisation status, setting) however there were insufficient study data available. We had also planned to adjust for possible sources of heterogeneity by adding them as covariates to the bivariate model. However, we could not do the meta-regression as we did not have enough studies to warrant the addition of variables. Assessment of reporting bias was not included in this review, as funnel plots have been shown to be misleading for reviews of diagnostic test accuracy.^{18,19}

Results

Figure 1 shows the flowchart of study selection. We identified 1969 unique papers, of which 422 had a full text review. Forty-seven studies met inclusion criteria for this review and contained sufficient data in the published article for complete data extraction. Fourteen further papers were identified with potential unpublished data. The authors of these papers were contacted, of which 6 provided the necessary information. Overall 53 papers were included in descriptive analysis and meta-analysis (where possible).

Table 1²⁰⁻⁷² summarises characteristics of included studies. The 53 studies included 23796 participants, of whom 4149 (17.4%) had a laboratory diagnosis of pertussis. The proportion of study cohorts with laboratory-confirmed pertussis ranged from 0.3-72.5% (mean 24.7%). Thirty-seven studies had a prospective design, 12 were retrospective and 4 were case-control. Inclusion criteria and reference standard varied widely across studies. Ten studies took place during a pertussis outbreak but the majority of papers did not report this. Those with at least one vaccination dose (recorded in 36 studies) ranged from 0 to 100% (mean 54.3%).

Risk of bias assessment with QUADAS-2 is summarised in Figure 2. Nineteen studies had low risk of bias/low applicability concerns throughout all 7 domains. Twenty-two studies were assessed at high risk of bias in at least one of the 4 domains.

Across the 53 included studies, 41 index tests were assessed for diagnostic accuracy, including 9 cough characteristics as well as other clinical and demographic features (Table 2). Forest plots were generated for each index test, which demonstrate the heterogeneity between studies. These are presented in e-Appendix 2.

After pre-specified meta-analysis exclusions (see methods), pooled estimates of sensitivity and specificity were generated (Table 3). Meta-analysis is not presented for immunisation due to wide heterogeneity in immunisations at different ages and different countries. Figure 3 shows Receiver Operating Characteristic (ROC) plots of the meta-analyses.

Discussion

Summary of evidence

Our meta-analysis demonstrates four key characteristics that are important in ruling in or out a clinical diagnosis of pertussis: paroxysmal cough, post-tussive vomiting, inspiratory whoop and absence of fever.

We found paroxysmal cough and absence of fever in adults have high sensitivity and low specificity. The clinical implication is that if an adult patient does not have paroxysmal cough, or does have a fever they are very unlikely to have pertussis - good 'rule out' tests.

Both post-tussive vomiting and whooping in adults have a low sensitivity and high specificity. The clinical implication is that if an adult patient has post-tussive vomiting or whooping, it raises suspicion of pertussis as a differential diagnosis – making both these good 'rule in' tests. Post-tussive vomiting in children, however, is only moderately sensitive and specific. This makes it much less helpful as a clinical diagnostic test than in adults.

The forest plots and summary ROC plots demonstrate large statistical heterogeneity within the data synthesised across the other index tests and interpretation of these data should be approached with caution. Index tests with a trend suggesting better sensitivity for diagnosis of pertussis include cough worse at night (sensitive but not specific in adults) and apnoea and cyanosis (moderately sensitive and specific in children). Lymphocytosis may be a relatively sensitive marker for pertussis infection in children, but only 3 studies assessed this and all used different thresholds.^{58,62,72} This finding would fit with what is already known about the effect of pertussis toxin in increasing the number of circulating white blood cells in infants with whooping cough.⁷³

Comparison with existing literature

There are a number of different clinical case definitions currently in use globally including those created by the United States Centers for Disease Control,⁶ Public Health England (PHE)⁷⁴ and World Health Organization.⁷ In common across all three sets of criteria is the cough lasting at least 14 days - an inclusion criterion of some of studies included in this review.^{27,33,38,41-43,51,56,59,69,71} Unfortunately, cough or symptom duration was used as an index test by some included studies, but often without indicating whether this was at presentation or overall. It could not be evaluated diagnostically. The presence of whooping or post-tussive vomiting is also common to the CDC, PHE and WHO clinical criteria, whilst paroxysms of coughing is included by CDC and WHO. This classical triad of symptoms are the index tests that our meta-analysis has shown should raise clinical suspicion of pertussis.

A person suspected by a physician of having pertussis is included in its own right as a criterion in the PHE and WHO criteria. This formed part of the inclusion criteria of a number of studies in this review,^{29,35,54} but was only used as an index test in 3 studies,^{35,39,44} which may explain the wide-ranging prevalence found across studies.

Apnoea and cyanosis are mentioned in relation to infants aged < 1 year in the CDC criteria, and are shown in our Forest plots (e-Appendix 2) to be moderately sensitive and specific in children.

There is one previous diagnostic accuracy systematic review of these classically described symptoms of pertussis (paroxysmal cough, post-tussive vomiting, and inspiratory whoop).⁷⁵ This was completed in 2010 and included three studies with patients over 5 years of age in a non-outbreak setting.^{38,49,63} Like our meta-analysis, it showed that paroxysmal cough has low specificity in older patients, and that the presence of whooping and post-tussive vomiting modestly increased the likelihood of pertussis. However, given all three symptoms had only relatively modest positive likelihood ratios between 1.1-1.9 the authors concluded that presence of these symptoms were of limited value in differentiating a pertussis diagnosis from other respiratory illnesses, and that overall clinical judgement was important. Our systematic

review extends this smaller study, by having broader inclusion criteria and considering other clinical symptoms as index tests.

Strengths and limitations

The broad eligibility criteria for this systematic review meant that we collected data from over fifty studies and were therefore able to include information on a large numbers of patients, making this the largest systematic review on this topic to date. However, this has also meant that there is a wide variation in study characteristics, which is likely to have contributed to the heterogeneity of our results.

A number of included studies were classed as high risk of bias for patient selection and were therefore not included in meta-analysis. Some listed features of pertussis as part of their inclusion criteria^{26,30,31,53,58,60,63,70} whilst others specifically recruited patients with suspected pertussis^{29,35,54} or included all patients who had had a laboratory test for pertussis.^{32,37,44,64,68,72}

Misclassification bias is likely to have been influential at both the study and review level as very few papers described the clinical features being assessed. There was also a lack of clarity in some papers as to whether a feature described was from the patient history or examination (e.g. fever). This is likely to have caused inconsistency in study data collection as well as synthesis of data in the systematic review – particularly when grouping similar characteristics together.

Use of single or a combination of reference standards also varied across studies. However, methods for all reference standards were compared to the CDC guidelines,¹³ and lack of transparency or deviation from these was reflected in the corresponding domain in the risk of bias assessment. In addition, many papers lacked details in the reporting of design setting (including whether or not there was an outbreak), and patient demographic (age, sex and immunisation status). It was therefore not possible to assess pre-test probability of pertussis in these studies.

For the purposes of systematic review we separated studies looking at adults and children, and excluded those that included patients of all ages. This is because it has been recognised that pertussis in adults and children does not present in the same way. However, an additional limitation is that our 'children' category includes studies with both older children and young infants who may also have very different presentations of pertussis.

Conclusions

There is substantial statistical heterogeneity between all included studies, which reflects heterogeneity in study designs used. As a result, meta-analysis was only possible of a limited number of clinical characteristics – predominantly in adult patients. The results of the meta-

analysis showed that recognising the classical triad of symptoms in adults remains helpful for clinicians. In adult patients the presence of whooping or post-tussive vomiting should rule in a possible diagnosis of pertussis, whereas the lack of a paroxysmal cough or the presence of fever should rule it out. In children, however, presence of post-tussive vomiting is much less helpful as a clinical diagnostic test and pooled estimates of sensitivity and specificity for other characteristics could not be calculated.

Further high quality research is needed to better understand which clinical characteristics can differentiate pertussis associated cough from other causes of cough. Particular consideration should be taken as to the entry criteria/patient population most likely to produce data that can be clinically useful. In addition, clear descriptions of clinical characteristics under testing are important to ensure consistent interpretation and reporting. Future research is likely to involve large prospective studies in primary care, as well as individual patient data analysis to assess the diagnostic utility of different symptoms in combination with the possibility of creating a scoring system to identify patients for definitive testing.

References

1. Wang K, Biring SS, Taylor K, et al. Montelukast for adults with post-infectious cough (MAC): A double-blind, randomized, placebo-controlled trial. *Lung*. 2014;192 (1):5-6.
2. Kapaskelis AM, Vouloumanou EK, Rafailidis PI, Hatzopoulou P, Nikita D, Falagas ME. High prevalence of antibody titers against *Bordetella pertussis* in an adult population with prolonged cough. *Respiratory Medicine*. 2008;102(11):1586-1591.
3. Black RE, Cousens S, Johnson HL, et al. Global, regional, and national causes of child mortality in 2008: a systematic analysis. *Lancet*. 2010;375(9730):1969-1987.
4. Lee GM, Lett S, Schauer S, et al. Societal costs and morbidity of pertussis in adolescents and adults. *Clinical Infectious Diseases*. 2004;39(11):1572-1580.
5. Wendelboe AM, Van Rie A, Salmaso S, Englund JA. Duration of immunity against pertussis after natural infection or vaccination. *Pediatr Infect Dis J*. 2005;24(5 Suppl):S58-61.
6. Pertussis / Whooping Cough (*Bordetella pertussis*) 2014 Case Definition. Centers for Disease Control and Prevention website. URL:<https://www.cdc.gov/nndss/conditions/pertussis/case-definition/2014/>. Accessed 02/16/2017.
7. WHO-recommended surveillance standard of pertussis. World Health Organisation website. URL:http://www.who.int/immunization/monitoring_surveillance/burden/vpd/surveillance_type/passive/pertussis_standards/en/. Accessed 02/16/2017.
8. Kilgore PE, Salim AM, Zervos MJ, Schmitt HJ. Pertussis: Microbiology, Disease, Treatment, and Prevention. *Clinical Microbiology Reviews*. 2016;29(3):449-486.
9. Hartzell JD, Blaylock JM. Whooping cough in 2014 and beyond: an update and review. *Chest*. 2014;146(1):205-214.
10. Wang K, Harnden A. Pertussis-induced cough. *Pulmonary Pharmacology & Therapeutics*. 2011;24(3):304-307.
11. Hewlett EL, Edwards KM. Pertussis - Not just for kids. *New England Journal of Medicine*. 2005;352(12):1215-1222.
12. Crowcroft NS, Pebody RG. Recent developments in pertussis. *The Lancet*. 367(9526):1926-1936.
13. Pertussis Diagnosis Confirmation. Centers for Disease Control and Prevention website. URL: <https://www.cdc.gov/pertussis/clinical/diagnostic-testing/diagnosis-confirmation.html>. Updated September 2015. Accessed 02/16/2017.
14. Wendelboe AM, Van Rie A. Diagnosis of pertussis: a historical review and recent developments. *Expert Review of Molecular Diagnostics*. 2006;6(6):857-864.
15. Black S. Epidemiology of pertussis. *Pediatric Infectious Disease Journal*. 1997;16(4 Suppl):S85-89.
16. Deeks JJ, Wisniewski S, Davenport C. Chapter 4: Guide to the contents of a Cochrane Diagnostic Test Accuracy Protocol. In: Deeks JJ, Bossuyt PM, Gatsonis C (editors), *Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy Version 1.0.0*. The Cochrane Collaboration, 2013. Available from: <http://srdta.cochrane.org/>.
17. Whiting PF, Rutjes AW, Westwood ME, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. *Ann Intern Med*. 2011;155(8):529-536.
18. Deeks JJ, Macaskill P, Irwig L. The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. *J Clin Epidemiol*. 2005;58(9):882-893.
19. Leeflang MM, Deeks JJ, Gatsonis C, Bossuyt PM, Cochrane Diagnostic Test Accuracy Working G. Systematic reviews of diagnostic test accuracy. *Ann Intern Med*. 2008;149(12):889-897.
20. Abu Raya B, Bamberger E, Kassis I, Kugelman A, Srugo I, Miron D. *Bordetella pertussis* infection attenuates clinical course of acute bronchiolitis. *Pediatric Infectious Disease Journal*. 2013;32(6):619-621.
21. Bellettini CV, de Oliveira AW, Tusset C, et al. Clinical, laboratorial and radiographic predictors of *Bordetella pertussis* infection Preditores clinicos, laboratoriais e radiograficos para infeccao por *Bordetella pertussis*. *Revista Paulista de Pediatria*. 2014;32(4):292-298.

22. Bock JM, Burtis CC, Poetker DM, Blumin JH, Frank MO. Serum immunoglobulin G analysis to establish a delayed diagnosis of chronic cough due to *Bordetella pertussis*. *Otolaryngology - Head & Neck Surgery*. 2012;146(1):63-67.
23. Bonhoeffer J, Bar G, Riffelmann M, Soler M, Heininger U. The role of *Bordetella* infections in patients with acute exacerbation of chronic bronchitis. *Infection*. 2005;33(1):13-17.
24. Cagney M, McIntyre PB, Heron L, Giammanco A, MacIntyre CR. The relationship between pertussis symptomatology, incidence and serology in adolescents. *Vaccine*. 2008;26(44):5547-5553.
25. Castagnini LA, Munoz FM. Clinical characteristics and outcomes of neonatal pertussis: a comparative study. *Journal of Pediatrics*. 2010;156(3):498-500.
26. Cengiz AB, Yildirim I, Ceyhan M, Secmeer G, Gur D, Kara A. Comparison of nasopharyngeal culture, polymerase chain reaction (PCR) and serological test for diagnosis of pertussis. *Turkish Journal of Pediatrics*. 2009;51(4):309-316.
27. Craig AS, Wright SW, Edwards KM, et al. Outbreak of pertussis on a college campus. *American Journal of Medicine*. 2007;120(4):364-368.
28. Crowcroft NS, Booy R, Harrison T, et al. Severe and unrecognised: pertussis in UK infants.[Erratum appears in Arch Dis Child. 2006 May;91(5):453]. *Archives of Disease in Childhood*. 2003;88(9):802-806.
29. Del Valle-Mendoza J, Casabona-Ore V, Petrozzi-Helasvuo V, et al. *Bordetella pertussis* diagnosis in children under five years of age in the Regional Hospital of Cajamarca, Northern Peru. *Journal of Infection in Developing Countries*. 2015;9(11):1180-1185.
30. Dinu S, Guillot S, Dragomirescu CC, et al. Whooping cough in South-East Romania: a 1-year study. *Diagnostic Microbiology & Infectious Disease*. 2014;78(3):302-306.
31. Ferronato AE, Gilio AE, Vieira SE. Respiratory viral infections in infants with clinically suspected pertussis. *Jornal de Pediatria*. 2013;89(6):549-553.
32. Fine AM, Reis BY, Nigrovic LE, et al. Use of population health data to refine diagnostic decision-making for pertussis. *Journal of the American Medical Informatics Association*. 2010;17(1):85-90.
33. Ghanaie RM, Karimi A, Sadeghi H, et al. Sensitivity and specificity of the World Health Organization pertussis clinical case definition. *International Journal of Infectious Diseases*. 2010;14(12):e1072-1075.
34. Gilberg S, Njamkepo E, Du Chatelet IP, et al. Evidence of *Bordetella pertussis* infection in adults presenting with persistent cough in a french area with very high whole-cell vaccine coverage. *Journal of Infectious Diseases*. 2002;186(3):415-418.
35. Granstrom G, Wretling B, Granstrom M. Diagnostic value of clinical and bacteriological findings in pertussis. *Journal of Infection*. 1991;22(1):17-26.
36. Greenberg D, Bamberger E, Ben-Shimol S, Gershtein R, Golan D, Srugo I. Pertussis is under diagnosed in infants hospitalized with lower respiratory tract infection in the pediatric intensive care unit. *Medical Science Monitor*. 2007;13(11):CR475-480.
37. Guinto-Ocampo H, Bennett JE, Attia MW. Predicting pertussis in infants. *Pediatric Emergency Care*. 2008;24(1):16-20.
38. Harnden A, Grant C, Harrison T, et al. Whooping cough in school age children with persistent cough: prospective cohort study in primary care. *BMJ*. 2006;333(7560):174-177.
39. Heininger U, Cherry JD, Eckhardt T, Lorenz C, Christenson P, Stehr K. Clinical and laboratory diagnosis of pertussis in the regions of a large vaccine efficacy trial in Germany. *Pediatric Infectious Disease Journal*. 1993;12(6):504-509.
40. Jackson LA, Cherry JD, Wang SP, Grayston JT. Frequency of serological evidence of *Bordetella* infections and mixed infections with other respiratory pathogens in university students with cough illnesses. *Clinical Infectious Diseases*. 2000;31(1):3-6.
41. Karagul A, Ogunc D, Midilli K, et al. Epidemiology of pertussis in adolescents and adults in Turkey. *Epidemiol Infect*. 2014:1-6.
42. Kayina V, Kyobe S, Katabazi FA, et al. Pertussis prevalence and its determinants among children with persistent cough in urban Uganda. *PLoS ONE [Electronic Resource]*. 2015;10(4):e0123240.
43. Koh MT, Liu CS, Chiu CH, et al. Under-recognized pertussis in adults from Asian countries: a cross-sectional seroprevalence study in Malaysia, Taiwan and Thailand. *Epidemiology & Infection*. 2016;144(6):1192-1200.

44. Mitchell AA, Liddell KG, Criggie W. Adult pertussis in a general practice. *Health Bulletin*. 2000;58(1):34-37.
45. Miyashita N, Akaike H, Teranishi H, et al. Diagnostic value of symptoms and laboratory data for pertussis in adolescent and adult patients. *BMC Infectious Diseases*. 2013;13:129.
46. Nicolai A, Nenna R, Stefanelli P, et al. Bordetella pertussis in infants hospitalized for acute respiratory symptoms remains a concern. *BMC Infectious Diseases*. 2013;13:526.
47. Nieves DJ, Singh J, Ashouri N, McGuire T, Adler-Shohet FC, Arrieta AC. Clinical and laboratory features of pertussis in infants at the onset of a California epidemic. *Journal of Pediatrics*. 2011;159(6):1044-1046.
48. Nuolivirta K, Koponen P, He Q, et al. Bordetella pertussis infection is common in nonvaccinated infants admitted for bronchiolitis. *Pediatric Infectious Disease Journal*. 2010;29(11):1013-1015.
49. Park WB, Park SW, Kim HB, Kim EC, Oh M, Choe KW. Pertussis in adults with persistent cough in South Korea. *European Journal of Clinical Microbiology & Infectious Diseases*. 2005;24(2):156-158.
50. Park S, Lee SH, Seo KH, et al. Epidemiological aspects of pertussis among adults and adolescents in a Korean outpatient setting: a multicenter, PCR-based study. *Journal of Korean Medical Science*. 2014;29(9):1232-1239.
51. Philipson K, Goodyear-Smith F, Grant CC, Chong A, Turner N, Stewart J. When is acute persistent cough in school-age children and adults whooping cough? A prospective case series study. *British Journal of General Practice*. 2013;63(613):e573-579.
52. Piedra PA, Mansbach JM, Jewell AM, et al. Bordetella pertussis is an uncommon pathogen in children hospitalized with bronchiolitis during the winter season. *Pediatric Infectious Disease Journal*. 2015;34(6):566-570.
53. Raymond J, Armengaud JB, Cosnes-Lambe C, et al. Pertussis in young infants: apnoea and intra-familial infection. *Clinical Microbiology & Infection*. 2007;13(2):172-175.
54. Rosenthal S, Strebel P, Cassidy P, Sanden G, Brusuelas K, Wharton M. Pertussis infection among adults during the 1993 outbreak in Chicago. *Journal of Infectious Diseases*. 1995;171(6):1650-1652.
55. Schlapfer G, Cherry JD, Heininger U, et al. Polymerase chain reaction identification of Bordetella pertussis infections in vaccinees and family members in a pertussis vaccine efficacy trial in Germany. *Pediatric Infectious Disease Journal*. 1995;14(3):209-214.
56. Schmitt-Grohe S, Cherry JD, Heininger U, Uberall MA, Pineda E, Stehr K. Pertussis in German adults. *Clinical Infectious Diseases*. 1995;21(4):860-866.
57. Senzilet LD, Halperin SA, Spika JS, et al. Pertussis is a frequent cause of prolonged cough illness in adults and adolescents. *Clinical Infectious Diseases*. 2001;32(12):1691-1697.
58. Shojaei J, Saffar M, Hashemi A, Ghorbani G, Rezai M, Shahmohammadi S. Clinical and laboratory features of pertussis in hospitalized infants with confirmed versus probable pertussis cases. *Annals of Medical & Health Sciences Research*. 2014;4(6):910-914.
59. Siriyakorn N, Leethong P, Tantawichien T, et al. Adult pertussis is unrecognized public health problem in Thailand. *BMC Infectious Diseases*. 2016;16:25.
60. Stefanoff P, Paradowska-Stankiewicz IA, Lipke M, et al. Incidence of pertussis in patients of general practitioners in Poland. *Epidemiology & Infection*. 2014;142(4):714-723.
61. Steketee RW, Burstyn DG, Wassilak SG, et al. A comparison of laboratory and clinical methods for diagnosing pertussis in an outbreak in a facility for the developmentally disabled. *Journal of Infectious Diseases*. 1988;157(3):441-449.
62. Strebel PM, Cochi SL, Farizo KM, Payne BJ, Hanauer SD, Baughman AL. Pertussis in Missouri: evaluation of nasopharyngeal culture, direct fluorescent antibody testing, and clinical case definitions in the diagnosis of pertussis. *Clinical Infectious Diseases*. 1993;16(2):276-285.

63. Strebel P, Nordin J, Edwards K, et al. Population-based incidence of pertussis among adolescents and adults, Minnesota, 1995-1996. *Journal of Infectious Diseases*. 2001;183(9):1353-1359.
64. Tarr GAM, Eickhoff JC, Koepke R, Hopfensperger DJ, Davis JP, Conway JH. Using a Bayesian Latent Class Model to Evaluate the Utility of Investigating Persons with Negative Polymerase Chain Reaction Results for Pertussis. *American Journal of Epidemiology*. 2013;178(2):309-318.
65. Teepe J, Broekhuizen BDL, Ieven M, et al. Prevalence, diagnosis, and disease course of pertussis in adults with acute cough: a prospective, observational study in primary care. *British Journal of General Practice*. 2015;65(639):e662-667.
66. van den Brink G, Wishaupt JO, Douma JC, Hartwig NG, Versteegh FG. Bordetella pertussis: an underreported pathogen in pediatric respiratory infections, a prospective cohort study. *BMC Infectious Diseases*. 2014;14:526.
67. Wirsing von Konig CH, Rott H, Bogaerts H, Schmitt HJ. A serologic study of organisms possibly associated with pertussis-like coughing. *Pediatric Infectious Disease Journal*. 1998;17(7):645-649.
68. Waters V, Jamieson F, Richardson SE, Finkelstein M, Wormsbecker A, Halperin SA. Outbreak of atypical pertussis detected by polymerase chain reaction in immunized preschool-aged children. *Pediatric Infectious Disease Journal*. 2009;28(7):582-587.
69. Wright SW, Edwards KM, Decker MD, Zeldin MH. Pertussis infection in adults with persistent cough. *JAMA*. 1995;273(13):1044-1046.
70. Wymann MN, Richard JL, Vidondo B, Heininger U. Prospective pertussis surveillance in Switzerland, 1991-2006. *Vaccine*. 2011;29(11):2058-2065.
71. Yildirim I, Ceyhan M, Kalayci O, et al. Frequency of pertussis in children with prolonged cough. *Scandinavian Journal of Infectious Diseases*. 2008;40(4):314-319.
72. Zouari A, Smaoui H, Brun D, et al. Prevalence of Bordetella pertussis and Bordetella parapertussis infections in Tunisian hospitalized infants: results of a 4-year prospective study. *Diagnostic Microbiology & Infectious Disease*. 2012;72(4):303-317.
73. Carbonetti NH. Pertussis leukocytosis: mechanisms, clinical relevance and treatment. *Pathog Dis*. 2016;74(7).
74. Pertussis factsheet for healthcare professionals. UK Government website. URL: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/562472/HCW_Factsheet_Pertussis.pdf. Published October 2013. Updated October 2016. Accessed 02/16/2017.
75. Cornia PB, Hersh AL, Lipsky BA, Newman TB, Gonzales R. Does this coughing adolescent or adult patient have pertussis? *JAMA*. 2010;304(8):890-896.

Figure legends

Figure 1.

Flow of the citations reviewed in the course of this systematic review.

Figure 2.

Risk of bias and applicability concerns summary: review authors' judgements about each domain for each included study.

Figure 3.

Summary Receiver Operating Characteristic plots depicting meta-analysis of various clinical characteristics in adults and children. The summary point represents the summary sensitivity and specificity, the 95% confidence region represents the 95% confidence intervals of the summary sensitivity and specificity and the 95% prediction region represents the 95% confidence interval of sensitivity and specificity of each individual study included in the analysis. Individual study estimates are also plotted indicating individual sensitivity and specificity with the size of the marker scaled according to the total number in each study.

Table 1. Characteristics of 53 included studies

Overview of all included studies. For more detailed characteristics, see e-Table 1

Study	Country (ies)	Setting	Inclusion criteria	Study type	Laboratory test				Total number of participants	Age category	Number (%) laboratory confirmed pertussis
					Culture	Serology	PCR	DFA			
Abu Raya et al ⁵	Israel	Secondary care	<= 4 days of clinically diagnosed acute bronchiolitis	Case control		□	✗		120	Children	23 (19.17)
Bellettini et al ⁶	Brazil	Multiple settings	Any patient tested for pertussis during study period	Retrospective			✗		222	Children	161 (72.52)
Bock et al ⁷	USA	Multiple settings	Chronic cough (>8 weeks)	Retrospective		✗			48	Adults	19 (39.58)
Bonhoeffer et al ⁸	Switzerland	Multiple settings	Acute exacerbation of chronic bronchitis	Prospective	✗	✗	✗		26	Adults	8 (30.77)
Cagney et al ⁹	Australia	Vaccine trial cohort	Participants of vaccine trial	Retrospective		✗			346	Children	5 (1.45)
Castagnini et al ¹⁰	USA	Secondary care	Pertussis PCR positive (cases) Alternative diagnosis (controls)	Case control			✗		66	Children	33 (50.00)
Gengiz et al ¹¹	Turkey	Secondary care	<ul style="list-style-type: none"> • Cough >= 7 days • Paroxysmal cough • Cough + whoop/vomiting/apnoea 	Prospective	✗	✗	✗		35	Children	26 (5.71)
Craig et al ¹²	USA	Primary care	Cough > 2 weeks	Prospective	✗	✗	✗	✗	37	Adults	10 (27.03)
Crowcroft ¹³	UK	Secondary care	Admitted to PICU with respiratory failure, apnoea +/- bradycardia or acute life threatening episode	Prospective	✗	✗	✗		126	Children	25 (19.84)
Del Valle-Mendoza et al ¹⁴	Peru	Secondary care	Clinically diagnosed with whooping cough	Prospective	✗		✗		133	Children	51 (38.35)
Dinu et al ¹⁵	Romania	Multiple settings	Cough > 1 week plus one of: <ul style="list-style-type: none"> • Paroxysmal cough • Fever • Nocturnal cough • Apnoea • Post-tussive emesis • Facial cyanosis 	Prospective	✗	✗	✗		51	Both	32 (62.75)
Ferronato et al ¹⁶	Brazil	Secondary care	<ul style="list-style-type: none"> • Dry cough > 2 weeks plus inspiratory stridor • Paroxysmal cough • Vomiting after coughing 	Retrospective	✗		✗		34	Children	22 (64.71)
Fine et al ¹⁷	USA	Emergency department	Any patient tested for pertussis during study period	Retrospective	✗				443	Children	38 (8.58)

Ghanaie et al ¹⁸	Iran	Schools	Cough >= 2 weeks	Prospective	✗		✗		328	Children	21 (6.40)
Gilberg et al ¹⁹	France	Primary care	Cough 7-31 days	Prospective	✗	✗	✗		217	Adults	70 (32.26)
Granstrom et al ²⁰	Sweden	Secondary care	Patients with suspected pertussis	Prospective	✗	✗			285	Both	163 (57.19)
Greenberg et al ²¹	Israel	Secondary care	PICU patients with LRTI as their primary or secondary diagnosis on discharge data	Retrospective			✗		74	Children	11 (14.86)
Guinto-Ocampo et al ²²	USA	Not reported	Any patient tested for pertussis during study period	Retrospective	✗		✗	✗	141	Children	18 (12.77)
Harnden et al ²³	UK	Primary care	Cough >= 2 weeks	Prospective		✗			172	Children	64 (37.21)
Heininger et al ²⁴	Germany	Primary care	Coughing child or household contact	Prospective	✗				3629	Children	601 (16.56)
Jackson et al ²⁵	USA	Primary care	<ul style="list-style-type: none"> Cough >= 5 days Acute respiratory infection judged to be more severe than common cold 	Prospective		✗		□	319	Adults	47 (14.73)
Karagul et al ²⁶	Turkey	Secondary care	Cough >= 2 weeks	Prospective	✗		✗		214	Adults	15 (7.01)
Kayina et al ²⁷	Uganda	Multiple settings	Cough >= 2 weeks	Prospective		✗	✗		449	Children	67 (14.92)
Koh et al ²⁸	Malaysia, Thailand, Taiwan	Multiple settings	Cough >= 2 weeks	Prospective		✗			312	Adults	16 (5.13)
Mitchell et al ²⁹	UK	Primary care	Any patient tested for pertussis during study period	Retrospective		✗			56	Adults	20 (35.71)
Miyashita et al ³⁰	Japan	Secondary care	Cough	Prospective		✗	✗		1315	Adults	183 (13.92)
Nicolai et al ³¹	Italy	Emergency department	Pertussis PCR positive (cases) RSV positive and pertussis negative (controls)	Case control			✗		38	Children	19 (50.00)
Nieves et al ³²	USA	Secondary care	Pertussis PCR positive (cases) RSV/flu positive (controls)	Case control	✗		✗	✗	126	Children	32 (25.40)
Nuolivirta et al ³³	Finland	Secondary care	Clinical diagnosis of bronchiolitis	Retrospective			✗	✗	142	Children	12 (8.45)
Park et al (2005) ³⁴	South Korea	Multiple settings	Cough 1-12 weeks	Prospective	✗		✗		102	Adults	3 (2.94)
Park et al (2014) ³⁵	Korea	Multiple settings	Cough <= 30 days	Prospective	✗		✗		490	Adults	34 (6.94)
Philipson et al ³⁶	New Zealand	Primary care	Cough > 2 weeks	Prospective		✗			222	Both	23 (10.36)
Piedra et al ³⁷	USA	Secondary care	Clinical diagnosis of bronchiolitis	Prospective			✗		1405	Children	4 (0.28)
Raymond et al ³⁸	France	Secondary care	<ul style="list-style-type: none"> Hospitalised with apnoea +/- cough Paroxysmal or vomiting cough 	Prospective			✗		41	Children	16 (39.02)
Rosenthal et al ³⁹	USA	Primary care	Cough > 6 days or suspected pertussis	Prospective	✗	✗			38	Adults	10 (26.32)
Schlapfer et al ⁴⁰	Germany	Vaccine trial cohort	Cough >= 1 week	Prospective	✗		✗		546	Both	110 (20.15)
Schmitt-Grohe et al ⁴¹	Germany	Vaccine trial cohort	Cough > 2 weeks	Prospective	✗	✗	✗		203	Adults	64 (31.53)
Senzilet et al ⁴²	Canada	Multiple settings	Cough 1-8 weeks	Prospective	✗	✗	✗		442	Adults	88 (19.91)

Shojaei et al ⁴³	Iran	Secondary care	Cough \geq 2 weeks with at least one pertussis associated symptom	Retrospective	*		*	118	Children	19 (16.10)
Siriyakorn et al ⁴⁴	Thailand	Secondary care	Cough > 2 weeks	Prospective		*	*	76	Adults	14 (18.42)
Stefanoff et al ⁴⁵	Poland	Primary care	Cough \geq 2 weeks At least one of <ul style="list-style-type: none"> • Paroxysms • Inspiratory whooping • Post-tussive vomiting without any apparent cause 	Prospective		*	*	1232	Both	288 (23.38)
Steketee et al ⁴⁶	USA	Setting of outbreak	Not clear	Prospective	*	*		255	Adults	107 (41.96)
Strebel et al (1993) ⁴⁷	USA	Multiple settings	Cough	Retrospective	*			88	Children	33 (37.50)
Strebel et al (2001) ⁴⁸	USA	Primary care	Cough 7-34 days or acute paroxysmal cough	Prospective	*	*	*	212	Adults	27 (12.74)
Tarr et al ⁴⁹	USA	Multiple settings	Any patient tested for pertussis during study period	Retrospective			*	250	Children	24 (9.60)
Teepe et al ⁵⁰	12 European Countries	Primary care	Cough \leq 28 days	Prospective		*	*	3074	Adults	93 (3.03)
van den Brink et al ⁵¹	Netherlands	Secondary care	Suspected acute respiratory tract infection	Prospective			*	306	Children	14 (4.58)
Wirsing von König et al ⁵²	Germany	Vaccine trial cohort	Cough \geq 1 week	Prospective	*	*		164	Children	112 (68.29)
Waters et al ⁵³	Canada	Multiple settings	Any patient tested for pertussis during study period	Case control	*		*	485	Children	189 (38.97)
Wright et al ⁵⁴	USA	Emergency department	Cough \geq 2 weeks	Prospective	*	*		75	Adults	16 (21.33)
Wymann et al ⁵⁵	Switzerland	Primary care	Cough lasting \geq 2 weeks with either <ul style="list-style-type: none"> • Epidemiological link to a pertussis case • At least one pertussis associated symptom • Clinical judgement 	Prospective			*	3721	Children	904 (24.29)
Yildirim et al ⁵⁶	Turkey	Secondary care	Cough > 2 weeks	Prospective	*	*	*	148	Children	25 (16.89)
Zouari et al ⁵⁷	Tunisia	Multiple settings	Any patient tested for pertussis during study period	Prospective	*	*	*	599	Children	120 (20.03)

Table 2. Index tests

Clinical characteristics, examination findings and patient demographics, and number of studies in which these were recorded

	Index test	Number of studies
Cough characteristic	Paroxysmal cough	36
	Post-tussive vomiting	36
	Whooping cough	28
	Worse at night	16
	Productive cough	12
	Wheeze	12
	Any cough	7
	Cough duration	6
Other respiratory symptoms/findings	Stridor	3
	Apnoea	21
	Cyanosis	16
	Rhinorrhoea	10
	Shortness of breath	9
	URTI symptoms	6
	Respiratory distress/hypoxia	5
	Chest crackles	5
	Sore throat	5
	Sneezing	4
	Sinus pain	3
	Hoarseness	2
Other clinical features	Post-tussive gagging	2
	Fever	28
	Headache	5
	Chest pain	5
	Feeding difficulties	4
	Lymphocytosis	4
	Facial discolouration	3
	Myalgia	3
	Conjunctival changes	3
	White blood cell count	3
	Fatigue	2
	Sweating	2
	Seizure	2
Clinical judgement	Post-tussive syncope	2
	Meets CDC/WHO clinical definition	8
Patient demographics	Clinical suspicion	2
	Vaccinated	19
	Exposure to contact	16
	Co-morbidity	6
	Smoking	5
	Previous whooping cough	4

Table 3. Meta-analysis

Pooled estimates of sensitivity and specificity

Clinical feature on which meta- analysis performed	Age category	Number of studies	Sensitivity % (95% CI)	Specificity % (95% CI)	Positive likelihood ratio (95% CI)	Negative likelihood ratio (95% CI)
Paroxysmal cough	Adults	7	93.2 (83.2-97.4)	20.6 (14.7-28.1)	1.17 (1.10-1.25)	0.33 (0.15-0.71)
Post-tussive vomiting	Adults	8	32.5 (24.5-41.6)	77.7 (73.1-81.7)	1.45 (1.19-1.79)	0.87 (0.79-0.96)
Inspiratory whoop	Adults	7	29.8 (18.0-45.2)	79.5 (69.4-86.9)	1.46 (1.07-1.97)	0.88 (0.77-1.00)
Absence of fever	Adults	5	81.8 (72.2-88.7)	18.8 (8.1-37.9)	1.01 (0.86-1.18)	0.97 (0.49-1.90)
Post-tussive vomiting	Children	6	60.0 (40.3-77.0)	66.0 (52.5-77.3)	1.76 (1.26-2.48)	0.61 (0.40-0.91)

Figure 1.






Figure 2.


	Risk of Bias				Applicability Concerns		
	Patient Selection	Index Test	Reference Standard	Flow and Timing	Patient Selection	Index Test	Reference Standard
Abu Raya 2013	?	?	+	-	-	+	+
Bellettini 2014	?	?	+	-	-	?	+
Bock 2012	?	?	?	?	?	+	+
Bonhoeffer 2005	?	+	+	+	-	-	+
Cagney 2008	+	-	+	+	+	-	+
Castagnini 2010	-	?	+	-	-	+	+
Cengiz 2009	+	+	+	+	+	+	+
Craig 2007	+	+	+	+	+	+	+
Crowcroft 2003	?	+	-	?	-	+	+
Del Valle Mendoza 2015	+	+	+	+	+	+	+
Dinu 2014	-	+	+	+	+	+	+
Ferronato 2013	-	?	?	-	-	?	?
Fine 2010	-	+	?	+	-	+	+
Ghanaie 2010	+	+	+	+	+	+	+
Gilberg 2002	+	+	+	+	+	+	+
Granstrom 1991	?	+	+	+	?	+	+
Greenberg 2007	+	?	+	+	-	+	+
Guinto-Ocampo 2008	-	?	-	?	?	+	+
Harnden 2006	+	+	+	+	+	+	+
Heininger 1993	+	+	+	+	+	+	+
Jackson 2000	?	?	-	?	+	+	-
Karagul 2014	+	-	+	+	+	+	+
Kayina 2015	+	+	+	+	+	+	+
Koh 2016	+	+	-	+	+	+	-
Mitchell 2000	?	-	+	+	+	+	+
Myashita 2013	+	+	+	+	+	+	+
Nicholai 2013	-	?	+	-	-	+	+
Nieves 2011	-	-	?	?	-	+	?
Nuolivirta 2010	?	-	+	+	-	+	+
Park (A) 2005	+	+	+	+	+	+	+
Park (B) 2014	+	+	+	+	+	+	+
Philipson 2013	+	+	+	+	+	+	+
Piedra 2015	+	+	+	+	-	+	+
Raymond 2007	+	?	+	+	-	?	+
Rosenthal 1995	+	+	+	+	+	+	+
Schlapfer 1995	+	+	?	+	+	+	?
Schmitt-Grohe 1995	-	+	+	-	+	+	+
Senzilet 2001	?	-	+	-	+	-	+
Shojaei 2014	+	?	?	+	+	?	?
Siriyakorn 2016	+	+	+	+	+	+	+
Stefanoff 2014	+	+	?	+	-	+	?
Steketee 1988	-	+	?	+	-	+	?
Strebel (A) 1993	?	?	+	+	?	+	+
Strebel (B) 2001	?	+	+	+	?	+	+
Tarr 2013	?	-	?	+	?	+	+
Teepe 2015	+	+	+	+	+	+	+
van den Brink 2014	+	+	+	+	+	+	+
Waters 2009	-	-	+	-	?	+	+
Wirsing von Konig 1998	?	+	?	-	?	+	?
Wright 1995	+	+	+	+	+	+	+
Wymann 2011	+	+	+	+	+	+	+
Yildirim 2008	+	+	+	+	+	+	+
Zouari 2012	?	+	+	+	-	+	+

● High ? Unclear ● Low


Figure 3.




Paroxysmal cough (adults)




Absence of fever (adults)



Post-tussive vomiting (adults)



Whooping cough (adults)



Post-tussive vomiting (children)

Abbreviations list

CDC	Center for Disease Control
DFA	direct fluorescent antibody test
PCR	polymerase chain reaction
PHE	Public Health England
ROC	Receiver Operating Characteristic
WHO	World Health Organization

ACCEPTED MANUSCRIPT


CHEST® Online Supplement

e-Table 1

Study	Country (ies)	Setting	Inclusion criteria	Study type	Pertussis outbreak	Dates of recruitment	Laboratory test				Total number of participants	Age range	Age category	% Male	Number (%) laboratory confirmed pertussis
							Culture	Serology	PCR	DFA					
Abu Raya et al ⁵	Israel	Secondary care	<= 4 days of clinically diagnosed acute bronchiolitis	Case control	Not recorded	2005-2006			*	120	0-52 weeks	Children	64.17%	23 (19.17)	
Bellettini et al ⁶	Brazil	Multiple settings	Any patient tested for pertussis during study period	Retrospective	Not recorded	2011-2013			*	222	Not recorded	Children	Not recorded	161 (72.52)	
Bock et al ⁷	USA	Multiple settings	Chronic cough (>8 weeks)	Retrospective	No	2007-2011		*		48	20-88 years	Adults	35.42%	19 (39.58)	
Bonhoeffer et al ⁸	Switzerland	Multiple settings	Acute exacerbation of chronic bronchitis	Prospective	Not recorded	2000-2002	*	*	*	26	34-86 years	Adults	Not recorded	8 (30.77)	
Cagney et al ⁹	Australia	Vaccine trial cohort	Participants of vaccine trial	Retrospective	Yes	1999-2000		*		346	Not recorded	Children	67.98%	5 (1.45)	
Castagnini et al ¹⁰	USA	Secondary care	Pertussis PCR positive (cases) Alternative diagnosis (controls)	Case control	Not recorded	2000-2007			*	66	12-30 days	Children	48.48%	33 (50.00)	
Cengiz et al ¹¹	Turkey	Secondary care	• Cough >= 7 days • Paroxysmal cough • Cough + whoop/vomiting/apnoea	Prospective	Not recorded	2005-2006	*	*	*	35	2 months - 13 years	Children	65.71%	26 (5.71)	
Craig et al ¹²	USA	Primary care	Cough > 2 weeks	Prospective	Yes	Not recorded	*	*	*	37	18-22 years	Adults	43.24%	10 (27.03)	
Crowcroft ¹³	UK	Secondary care	Admitted to PICU with respiratory failure, apnoea +/- bradycardia or acute life threatening episode	Prospective	No	1998-1999	*	*	*	126	Not recorded	Children	Not recorded	25 (19.84)	
Del Valle-Mendoza et al ¹⁴	Peru	Secondary care	Clinically diagnosed with whooping cough Cough > 1 week plus one of:	Prospective	No	2010-2013	*		*	133	<3months - 5 years	Children	54.14%	51 (38.35)	
Dinu et al ¹⁵	Romania	Multiple settings	• Paroxysmal cough • Fever • Nocturnal cough • Apnoea • Post-tussive emesis • Facial cyanosis	Prospective	Not recorded	2012-2013	*	*	*	51	3 months - 75 years	Both	43.14%	32 (62.75)	
Ferronato et al ¹⁶	Brazil	Secondary care	• Dry cough > 2 weeks plus inspiratory stridor • Paroxysmal cough • Vomiting after coughing	Retrospective	Not recorded	2009-2012	*		*	34	Not recorded	Children	41.18%	22 (64.71)	
Fine et al ¹⁷	USA	Emergency department	Any patient tested for pertussis during study period	Retrospective	Not recorded	2003-2007	*			443	Not recorded	Children	53.05%	38 (8.58)	
Ghanaie et al ¹⁸	Iran	Schools	Cough >= 2 weeks	Prospective	Not recorded	2007-2008	*		*	328	6-14 years	Children	54.88%	21 (6.40)	
Gilberg et al ¹⁹	France	Primary care	Cough 7-31 days	Prospective	Not recorded	1999	*	*	*	217	18-88 years	Adults	27.19%	70 (32.26)	
Granstrom et al ²⁰	Sweden	Secondary care	Patients with suspected pertussis	Prospective	Not recorded	1986-1987	*	*		285	0.2-63.2 years	Both	50.53%	163 (57.19)	
Greenberg et al ²¹	Israel	Secondary care	PICU patients with LRTI as their primary or secondary diagnosis on discharge data	Retrospective	Not recorded	1998-2001			*	74	Not recorded	Children	63.51%	11 (14.86)	

Online supplements are not copyedited prior to posting and the author(s) take full responsibility for the accuracy of all data.



Guinto-Ocampo et al ²²	USA	Not reported	Any patient tested for pertussis during study period	Retrospective	Not recorded	2001-2005	* * *	141	7-286 days	Children	62.41%	18 (12.77)
Harnden et al ²³	UK	Primary care	Cough >= 2 weeks	Prospective	Not recorded	2001-2005	*	172	5-16.9 years	Children	54.65%	64 (37.21)
Heininger et al ²⁴	Germany	Primary care	Coughing child or household contact	Prospective	Not recorded	1991-1992	*	3629	Not recorded	Children	Not recorded	601 (16.56)
Jackson et al ²⁵	USA	Primary care	<ul style="list-style-type: none"> Cough >= 5 days Acute respiratory infection judged to be more severe than common cold 	Prospective	Not recorded	Not recorded	*	319	Not recorded	Adults	43.89%	47 (14.73)
Karagui et al ²⁶	Turkey	Secondary care	Cough >= 2 weeks	Prospective	Not recorded	2010-2011	* *	214	10- 39 years	Adults	44.86%	15 (7.01)
Kayina et al ²⁷	Uganda	Multiple settings	Cough >= 2 weeks	Prospective	Not recorded	2013	* *	449	3 months - 12 years	Children	51.00%	67 (14.92)
Koh et al ²⁸	Malaysia, Thailand, Taiwan	Multiple settings	Cough >= 2 weeks	Prospective	Not recorded	2012-2013	*	312	19-83 years	Adults	32.69%	16 (5.13)
Mitchell et al ²⁹	UK	Primary care	Any patient tested for pertussis during study period	Retrospective	No	1995-1996	*	56	16-60 years	Adults	Not recorded	20 (35.71)
Miyashita et al ³⁰	Japan	Secondary care	Cough	Prospective	No	2005-2012	* *	1315	16-79 years	Adults	43.65%	183 (13.92)
Nicolai et al ³¹	Italy	Emergency department	<ul style="list-style-type: none"> Pertussis PCR positive (cases) RSV positive and pertussis negative (controls) 	Case control	Not recorded	2008-2010	*	38	20-187 days	Children	31.58%	19 (50.00)
Nieves et al ³²	USA	Secondary care	<ul style="list-style-type: none"> Pertussis PCR positive (cases) RSV/flu positive (controls) 	Case control	Not recorded	2009-2010	* * *	126	< 3 months	Children	Not recorded	32 (25.40)
Nuolivirta et al ³³	Finland	Secondary care	Clinical diagnosis of bronchiolitis	Retrospective	Not recorded	2001-2004	* *	142	<4 weeks - 6 months	Children	50.00%	12 (8.45)
Park et al (2005) ³⁴	South Korea	Multiple settings	Cough 1-12 weeks	Prospective	Not recorded	2002-2003	* *	102	19-83 years	Adults	52.94%	3 (2.94)
Park et al (2014) ³⁵	Korea	Multiple settings	Cough <= 30 days	Prospective	No	2011-2012	* *	490	Not recorded	Adults	27.35%	34 (6.94)
Philipson et al ³⁶	New Zealand	Primary care	Cough > 2 weeks	Prospective	Not recorded	2011	*	222	5 - 49 years	Both	36.73%	23 (10.36)
Piedra et al ³⁷	USA	Secondary care	Clinical diagnosis of bronchiolitis	Prospective	No	2007-2010	*	1405	< 6 months	Children	58.29%	4 (0.28)
Raymond et al ³⁸	France	Secondary care	<ul style="list-style-type: none"> Hospitalised with apnoea +/- cough Paroxysmal or vomiting cough 	Prospective	Yes	2004-2005	*	41	< 4 months	Children	Not recorded	16 (39.02)
Rosenthal et al ³⁹	USA	Primary care	Cough > 6 days or suspected pertussis	Prospective	Yes	1993-1994	* *	38	13-81 years	Adults	Not recorded	10 (26.32)
Schlapfer et al ⁴⁰	Germany	Vaccine trial cohort	Cough >= 1 week	Prospective	Not recorded	1993-1994	* *	546	Not recorded	Both	Not recorded	110 (20.15)
Schmitt-Grohe et al ⁴¹	Germany	Vaccine trial cohort	Cough > 2 weeks	Prospective	Not recorded	1991-1994	* * *	203	18-79 years	Adults	31.53%	64 (31.53)
Senzilet et al ⁴²	Canada	Multiple settings	Cough 1-8 weeks	Prospective	Not recorded	1996-1997	* * *	442	12.3-88.4 years	Adults	30.54%	88 (19.91)
Shojaei et al ⁴³	Iran	Secondary care	Cough >= 2 weeks with at least one pertussis associated symptom	Retrospective	Yes	2008-2012	* *	118	Not recorded	Children	49.15%	19 (16.10)
Siriyakorn et al ⁴⁴	Thailand	Secondary care	Cough > 2 weeks	Prospective	Not recorded	2010-2011	* *	76	15-87 years	Adults	36.84%	14 (18.42)
Stefanoff et al ⁴⁵	Poland	Primary care	<ul style="list-style-type: none"> Cough >= 2 weeks At least one of <ul style="list-style-type: none"> Paroxysms Inspiratory whooping Post-tussive vomiting without any apparent cause 	Prospective	Not recorded	2009-2011	* *	1232	Not recorded	Both	37.42%	288 (23.38)
Steketee et al ⁴⁶	USA	Setting of outbreak	Not clear	Prospective	Yes	1984 -?	* *	255	Not recorded	Adults	Not recorded	107 (41.96)

Online supplements are not copyedited prior to posting and the author(s) take full responsibility for the accuracy of all data.


CHEST[®] Online Supplement


Strebel et al (1993) ⁴⁷	USA	Multiple settings	Cough	Retrospective	Yes	1989	*			88	Not recorded	Children	Not recorded	33 (37.50)
Strebel et al (2001) ⁴⁸	USA	Primary care	Cough 7-34 days or acute paroxysmal cough	Prospective	Not recorded	1995-1996	*	*	*	212	10-49 years	Adults	33.96%	27 (12.74)
Tarr et al ⁴⁹	USA	Multiple settings	Any patient tested for pertussis during study period	Retrospective	Yes	2010			*	250	Not recorded	Children	47.60%	24 (9.60)
Teepe et al ⁵⁰	12 European Countries	Primary care	Cough <= 28 days	Prospective	No	2007-2010		*	*	3074	NR	Adults	40.11%	93 (3.03)
van den Brink et al ⁵¹	Netherlands	Secondary care	Suspected acute respiratory tract infection	Prospective	Not recorded	2007-2009			*	306	0.1-89.4 months	Children	Not recorded	14 (4.58)
Wirsing von König et al ⁵²	Germany	Vaccine trial cohort	Cough >=1 week	Prospective	Not recorded	Not recorded	*	*		164	0-18	Children	Not recorded	112 (68.29)
Waters et al ⁵³	Canada	Multiple settings	Any patient tested for pertussis during study period	Case control	Yes	2005-2006	*		*	485	5 months - 14.9 years	Children	52.58%	189 (38.97)
Wright et al ⁵⁴	USA	Emergency department	Cough >= 2 weeks	Prospective	No	1992-1994	*	*		75	NR	Adults	34.67%	16 (21.33)
Wymann et al ⁵⁵	Switzerland	Primary care	Cough lasting >=2 weeks with either • Epidemiological link to a pertussis case • At least one pertussis associated symptom • Clinical judgement	Prospective	Yes	1991-2006			*	3721	NR	Children	Not recorded	904 (24.29)
Yildirim et al ⁵⁶	Turkey	Secondary care	Cough > 2 weeks	Prospective	No	2005-2006	*	*	*	148	<1-16	Children	56.76%	25 (16.89)
Zouari et al ⁵⁷	Tunisia	Multiple settings	Any patient tested for pertussis during study period	Prospective	Not recorded	2007-2011	*	*	*	599	1 day- 11months	Children	55.43%	120 (20.03)



e-Appendix 1. Search strategy for CINAHL

CINAHL


#	Query	Result
1	(MH "Whooping Cough")	1,067
2	(MH "Bordetella Pertussis")	81
3	TI (whooping cough or pertussis) AND AB (whooping cough or pertussis)	311
4	1 OR 2 OR 3	1,158
5	(MH "Cough")	2,455
6	(MH "Symptoms")	3,974
7	(MH "Respiratory Sounds")	1,249
8	TI ((cough* N5 (onset or time or duration or lasting or onset or hour? or day? or week? or length or long* or prolong* or persisten*))) OR AB ((cough* N5 (onset or time or duration or lasting or onset or hour? or day? or week? or length or long* or prolong* or persisten*)))	521
9	TI ((cough* N5 (rapid* or fast or speed or spell? or bout? or period? or frequen* or sound?))) OR AB ((cough* N5 (rapid* or fast or speed or spell? or bout? or period? or frequen* or sound?)))	231
10	TI ((cough* N5 (character* or feature? or presentation? or descri* or document*))) OR AB ((cough* N5 (character* or feature? or presentation? or descri* or document*)))	138
11	TI ((cough* N5 (sever* or intens* or type?))) OR AB ((cough* N5 (sever* or intens* or type?)))	162
12	TI ((cough N5 (productive or nonproductive or dry or explosive or reflex* or refractory or chronic* or vomit*))) OR AB ((cough N5 (productive or nonproductive or dry or explosive or reflex* or refractory or chronic* or vomit*)))	917
13	TI paroxysm* OR AB paroxysm*	2,208
14	TI whoop? OR AB whoop?	17
15	TI wheez* OR AB wheez*	1,521
16	TI gasp* OR AB gasp*	112
17	TI (((chest or respirat*) N2 sound*)) OR AB (((chest or respirat*) N2 sound*)) OR TI (stridor?) OR AB (stridor?)	48
18	TI ((posttussive or post-tussive or tussive)) OR AB ((posttussive or post-tussive or tussive)) OR TI (sputum) OR AB (sputum)	1,631
19	TI ((clinical exam* or physical exam* or chart review)) OR AB ((clinical exam* or physical exam* or chart review))	24,236
20	TI ((clinical N5 (sign? or symptom? or feature? or presentation or characteristic?))) OR AB ((clinical N5 (sign? or symptom? or feature? or presentation or characteristic?)))	22,820
21	TI ((physical N5 (sign? or symptom? or feature? or presentation or characteristic?))) OR AB ((physical N5 (sign? or symptom? or feature? or presentation or characteristic?)))	5,540
22	TI ((present* N5 (sign? or symptom? or feature? or characteristic?))) OR AB ((present* N5 (sign? or symptom? or feature? or characteristic?)))	7,447
23	TI ((symptom* N5 (time or duration or lasting or onset or hour? or day? or week? or length or long* or prolong* or persisten* or presentation))) OR AB ((symptom* N5 (time or duration or lasting or onset or hour? or day? or week? or length or long* or prolong* or persisten* or presentation)))	11,889
24	TI (sign? or symptom? or feature? or presentation or characteristic?)	38,216
25	TI (((household* OR house-hold*) N5 contact*)) OR AB (((household* OR house-hold*) N5 contact*))	252
26	5 OR 6 OR 7 OR 8 OR 9 OR 10 OR 11 OR 12 OR 13 OR 14 OR 15 OR 16 OR 17 OR 18 OR 19 OR 20 OR 21 OR 22 OR 23 OR 24 OR 25	104,390
27	4 AND 26	150


COUGH CHARACTERISTIC







Clinical characteristic	Described as	Forest plot										SROC plot	
Worse at night	Worse at night Nocturnal cough Night cough Mainly at night Disturbed sleep Awakened by cough	Study	TP	FP	FN	TN	Child/Adult	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)		
		Senzilet 2001	74	276	14	78	Adults	0.84 [0.75, 0.91]	0.22 [0.18, 0.27]				
		Siriyakorn 2016	3	15	11	47	Adults	0.21 [0.05, 0.51]	0.76 [0.63, 0.86]				
		Rosenthal 1995	8	23	2	5	Adults	0.80 [0.44, 0.97]	0.18 [0.06, 0.37]				
		Schmitt-Grohe 1995	36	70	28	69	Adults	0.56 [0.43, 0.69]	0.50 [0.41, 0.58]				
		Teepe 2015	68	1867	25	1109	Adults	0.73 [0.63, 0.82]	0.37 [0.36, 0.39]				
		Wright 1995	14	44	2	15	Adults	0.88 [0.62, 0.98]	0.25 [0.15, 0.38]				
		Steketee 1988	33	10	74	138	Adults	0.31 [0.22, 0.41]	0.93 [0.88, 0.97]				
		Gilberg 2002	60	46	9	7	Adults	0.87 [0.77, 0.94]	0.13 [0.05, 0.25]				
		Craig 2007	9	19	1	8	Adults	0.90 [0.55, 1.00]	0.30 [0.14, 0.50]				
		Myashita 2013	133	747	50	385	Adults	0.73 [0.66, 0.79]	0.34 [0.31, 0.37]				
		Koh 2016	11	211	5	85	Adults	0.69 [0.41, 0.89]	0.29 [0.24, 0.34]				
		Mitchell 2000	15	14	5	22	Adults	0.75 [0.51, 0.91]	0.61 [0.43, 0.77]				
		Stefanoff 2014	167	522	121	422	Both	0.58 [0.52, 0.64]	0.45 [0.41, 0.48]				
		Dinu 2014	26	11	5	8	Both	0.84 [0.66, 0.95]	0.42 [0.20, 0.67]				
Phillipson 2013	2	13	21	186	Both	0.09 [0.01, 0.28]	0.93 [0.89, 0.96]						
Tarr 2013	15	81	7	31	Children	0.68 [0.45, 0.86]	0.28 [0.20, 0.37]						
Productive cough	Productive cough Sputum (production) Coughing up phlegm	Study	TP	FP	FN	TN	Child/Adult	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)		
		Bonhoeffer 2005	8	17	0	1	Adults	1.00 [0.63, 1.00]	0.06 [0.00, 0.27]				
		Craig 2007	8	19	2	8	Adults	0.80 [0.44, 0.97]	0.30 [0.14, 0.50]				
		Jackson 2000	43	250	4	22	Adults	0.91 [0.80, 0.98]	0.08 [0.05, 0.12]				
		Koh 2016	6	180	10	116	Adults	0.38 [0.15, 0.65]	0.39 [0.34, 0.45]				
		Myashita 2013	67	378	116	754	Adults	0.37 [0.30, 0.44]	0.67 [0.64, 0.69]				
		Park (B) 2014	29	290	5	166	Adults	0.85 [0.69, 0.95]	0.36 [0.32, 0.41]				
		Rosenthal 1995	8	27	2	1	Adults	0.80 [0.44, 0.97]	0.04 [0.00, 0.18]				
		Schmitt-Grohe 1995	42	82	22	57	Adults	0.66 [0.53, 0.77]	0.41 [0.33, 0.50]				
		Wright 1995	12	41	4	18	Adults	0.75 [0.48, 0.93]	0.31 [0.19, 0.44]				
		Phillipson 2013	21	172	2	27	Both	0.91 [0.72, 0.99]	0.14 [0.09, 0.19]				
		Del Valle Mendoza 2015	1	0	50	82	Children	0.02 [0.00, 0.10]	1.00 [0.96, 1.00]				
		Harnden 2006	44	60	19	48	Children	0.70 [0.57, 0.81]	0.44 [0.35, 0.54]				








OTHER RESPIRATORY SYMPTOMS/FINDINGS













Clinical characteristic	Described as	Forest plot	SROC plot																														
Hoarseness	Hoarseness	<table border="1"> <thead> <tr> <th>Study</th> <th>TP</th> <th>FP</th> <th>FN</th> <th>TN</th> <th>Child/Adult</th> <th>Sensitivity (95% CI)</th> <th>Specificity (95% CI)</th> <th>Sensitivity (95% CI)</th> <th>Specificity (95% CI)</th> </tr> </thead> <tbody> <tr> <td>Siriyakorn 2016</td> <td>6</td> <td>32</td> <td>8</td> <td>30</td> <td>Adults</td> <td>0.43 [0.18, 0.71]</td> <td>0.48 [0.35, 0.61]</td> <td></td> <td></td> </tr> <tr> <td>Gilberg 2002</td> <td>31</td> <td>20</td> <td>34</td> <td>28</td> <td>Adults</td> <td>0.48 [0.35, 0.60]</td> <td>0.58 [0.43, 0.72]</td> <td></td> <td></td> </tr> </tbody> </table>	Study	TP	FP	FN	TN	Child/Adult	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)	Siriyakorn 2016	6	32	8	30	Adults	0.43 [0.18, 0.71]	0.48 [0.35, 0.61]			Gilberg 2002	31	20	34	28	Adults	0.48 [0.35, 0.60]	0.58 [0.43, 0.72]			<p>Legend ○ Child/Adult: Adults</p>
Study	TP	FP	FN	TN	Child/Adult	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)																								
Siriyakorn 2016	6	32	8	30	Adults	0.43 [0.18, 0.71]	0.48 [0.35, 0.61]																										
Gilberg 2002	31	20	34	28	Adults	0.48 [0.35, 0.60]	0.58 [0.43, 0.72]																										
Post-tussive gagging	Post-tussive gagging	<table border="1"> <thead> <tr> <th>Study</th> <th>TP</th> <th>FP</th> <th>FN</th> <th>TN</th> <th>Child/Adult</th> <th>Sensitivity (95% CI)</th> <th>Specificity (95% CI)</th> <th>Sensitivity (95% CI)</th> <th>Specificity (95% CI)</th> </tr> </thead> <tbody> <tr> <td>Strebel (B) 2001</td> <td>27</td> <td>132</td> <td>0</td> <td>53</td> <td>Adults</td> <td>1.00 [0.87, 1.00]</td> <td>0.29 [0.22, 0.36]</td> <td></td> <td></td> </tr> <tr> <td>Myashita 2013</td> <td>90</td> <td>259</td> <td>93</td> <td>873</td> <td>Adults</td> <td>0.49 [0.42, 0.57]</td> <td>0.77 [0.75, 0.80]</td> <td></td> <td></td> </tr> </tbody> </table>	Study	TP	FP	FN	TN	Child/Adult	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)	Strebel (B) 2001	27	132	0	53	Adults	1.00 [0.87, 1.00]	0.29 [0.22, 0.36]			Myashita 2013	90	259	93	873	Adults	0.49 [0.42, 0.57]	0.77 [0.75, 0.80]			<p>Legend ○ Child/Adult: Adults</p>
Study	TP	FP	FN	TN	Child/Adult	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)																								
Strebel (B) 2001	27	132	0	53	Adults	1.00 [0.87, 1.00]	0.29 [0.22, 0.36]																										
Myashita 2013	90	259	93	873	Adults	0.49 [0.42, 0.57]	0.77 [0.75, 0.80]																										

OTHER CLINICAL FEATURES

Clinical characteristic	Described as	Forest plot										SROC plot																																																																																																																																																																																																																																																																																									
Fever	Fever Fever with cutoff (37/37.2/38 C, 100.4 F variously) Temperature elevation History of fever Fever since onset of cough	<table border="1"> <thead> <tr> <th>Study</th> <th>TP</th> <th>FP</th> <th>FN</th> <th>TN</th> <th>Child/Adult</th> <th>Sensitivity (95% CI)</th> <th>Specificity (95% CI)</th> <th>Sensitivity (95% CI)</th> <th>Specificity (95% CI)</th> </tr> </thead> <tbody> <tr><td>Bonhoeffer 2005</td><td>3</td><td>5</td><td>5</td><td>13</td><td>Adults</td><td>0.38 [0.09, 0.76]</td><td>0.72 [0.47, 0.90]</td><td></td><td></td></tr> <tr><td>Craig 2007</td><td>2</td><td>9</td><td>8</td><td>18</td><td>Adults</td><td>0.20 [0.03, 0.56]</td><td>0.67 [0.46, 0.83]</td><td></td><td></td></tr> <tr><td>Karagul 2014</td><td>3</td><td>77</td><td>12</td><td>122</td><td>Adults</td><td>0.20 [0.04, 0.48]</td><td>0.61 [0.54, 0.68]</td><td></td><td></td></tr> <tr><td>Jackson 2000</td><td>10</td><td>92</td><td>37</td><td>180</td><td>Adults</td><td>0.21 [0.11, 0.36]</td><td>0.66 [0.60, 0.72]</td><td></td><td></td></tr> <tr><td>Myashita 2013</td><td>27</td><td>234</td><td>156</td><td>898</td><td>Adults</td><td>0.15 [0.10, 0.21]</td><td>0.79 [0.77, 0.82]</td><td></td><td></td></tr> <tr><td>Koh 2016</td><td>5</td><td>74</td><td>11</td><td>222</td><td>Adults</td><td>0.31 [0.11, 0.59]</td><td>0.75 [0.70, 0.80]</td><td></td><td></td></tr> <tr><td>Schmitt-Crohe 1995</td><td>12</td><td>53</td><td>62</td><td>244</td><td>Adults</td><td>0.16 [0.09, 0.27]</td><td>0.82 [0.77, 0.86]</td><td></td><td></td></tr> <tr><td>Park (B) 2014</td><td>2</td><td>21</td><td>32</td><td>435</td><td>Adults</td><td>0.06 [0.01, 0.20]</td><td>0.95 [0.93, 0.97]</td><td></td><td></td></tr> <tr><td>Teepe 2015</td><td>26</td><td>14</td><td>81</td><td>134</td><td>Adults</td><td>0.24 [0.17, 0.34]</td><td>0.91 [0.85, 0.95]</td><td></td><td></td></tr> <tr><td>Steketee 1988</td><td>60</td><td>206</td><td>228</td><td>738</td><td>Adults</td><td>0.21 [0.16, 0.26]</td><td>0.78 [0.75, 0.81]</td><td></td><td></td></tr> <tr><td>Wright 1995</td><td>4</td><td>149</td><td>10</td><td>143</td><td>Adults</td><td>0.29 [0.08, 0.58]</td><td>0.49 [0.43, 0.55]</td><td></td><td></td></tr> <tr><td>Granstrom 1991</td><td>7</td><td>15</td><td>156</td><td>107</td><td>Both</td><td>0.04 [0.02, 0.09]</td><td>0.88 [0.81, 0.93]</td><td></td><td></td></tr> <tr><td>Dinu 2014</td><td>4</td><td>3</td><td>27</td><td>16</td><td>Both</td><td>0.13 [0.04, 0.30]</td><td>0.84 [0.60, 0.97]</td><td></td><td></td></tr> <tr><td>Schlapfer 1995</td><td>0</td><td>298</td><td>4</td><td>1103</td><td>Both</td><td>0.00 [0.00, 0.60]</td><td>0.79 [0.76, 0.81]</td><td></td><td></td></tr> <tr><td>Stefanoff 2014</td><td>8</td><td>21</td><td>55</td><td>113</td><td>Both</td><td>0.13 [0.06, 0.23]</td><td>0.84 [0.77, 0.90]</td><td></td><td></td></tr> <tr><td>Castagnini 2010</td><td>1</td><td>5</td><td>32</td><td>28</td><td>Children</td><td>0.03 [0.00, 0.16]</td><td>0.85 [0.68, 0.95]</td><td></td><td></td></tr> <tr><td>Crowcroft 2003</td><td>11</td><td>45</td><td>14</td><td>56</td><td>Children</td><td>0.44 [0.24, 0.65]</td><td>0.55 [0.45, 0.65]</td><td></td><td></td></tr> <tr><td>Abu Raya 2013</td><td>7</td><td>43</td><td>16</td><td>53</td><td>Children</td><td>0.30 [0.13, 0.53]</td><td>0.55 [0.45, 0.65]</td><td></td><td></td></tr> <tr><td>Guinto-Ocampo 2008</td><td>1</td><td>14</td><td>15</td><td>89</td><td>Children</td><td>0.06 [0.00, 0.30]</td><td>0.86 [0.78, 0.92]</td><td></td><td></td></tr> <tr><td>Del Valle Mendoza 2015</td><td>20</td><td>28</td><td>31</td><td>54</td><td>Children</td><td>0.39 [0.26, 0.54]</td><td>0.66 [0.55, 0.76]</td><td></td><td></td></tr> <tr><td>Fine 2010</td><td>1</td><td>86</td><td>37</td><td>319</td><td>Children</td><td>0.03 [0.00, 0.14]</td><td>0.79 [0.74, 0.83]</td><td></td><td></td></tr> <tr><td>Ferronato 2013</td><td>3</td><td>4</td><td>19</td><td>8</td><td>Children</td><td>0.14 [0.03, 0.35]</td><td>0.67 [0.35, 0.90]</td><td></td><td></td></tr> <tr><td>Nicholai 2013</td><td>3</td><td>13</td><td>16</td><td>6</td><td>Children</td><td>0.16 [0.03, 0.40]</td><td>0.32 [0.13, 0.57]</td><td></td><td></td></tr> <tr><td>Kayna 2015</td><td>41</td><td>220</td><td>26</td><td>162</td><td>Children</td><td>0.61 [0.49, 0.73]</td><td>0.42 [0.37, 0.48]</td><td></td><td></td></tr> <tr><td>Nieves 2011</td><td>7</td><td>58</td><td>24</td><td>36</td><td>Children</td><td>0.23 [0.10, 0.41]</td><td>0.38 [0.28, 0.49]</td><td></td><td></td></tr> <tr><td>van den Brink 2014</td><td>26</td><td>1045</td><td>67</td><td>1931</td><td>Children</td><td>0.28 [0.19, 0.38]</td><td>0.65 [0.63, 0.67]</td><td></td><td></td></tr> <tr><td>Zouari 2012</td><td>361</td><td>1059</td><td>417</td><td>1365</td><td>Children</td><td>0.46 [0.43, 0.50]</td><td>0.56 [0.54, 0.58]</td><td></td><td></td></tr> <tr><td>Wymann 2011</td><td>6</td><td>13</td><td>10</td><td>46</td><td>Children</td><td>0.38 [0.15, 0.65]</td><td>0.78 [0.65, 0.88]</td><td></td><td></td></tr> </tbody> </table>	Study	TP	FP	FN	TN	Child/Adult	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)	Bonhoeffer 2005	3	5	5	13	Adults	0.38 [0.09, 0.76]	0.72 [0.47, 0.90]			Craig 2007	2	9	8	18	Adults	0.20 [0.03, 0.56]	0.67 [0.46, 0.83]			Karagul 2014	3	77	12	122	Adults	0.20 [0.04, 0.48]	0.61 [0.54, 0.68]			Jackson 2000	10	92	37	180	Adults	0.21 [0.11, 0.36]	0.66 [0.60, 0.72]			Myashita 2013	27	234	156	898	Adults	0.15 [0.10, 0.21]	0.79 [0.77, 0.82]			Koh 2016	5	74	11	222	Adults	0.31 [0.11, 0.59]	0.75 [0.70, 0.80]			Schmitt-Crohe 1995	12	53	62	244	Adults	0.16 [0.09, 0.27]	0.82 [0.77, 0.86]			Park (B) 2014	2	21	32	435	Adults	0.06 [0.01, 0.20]	0.95 [0.93, 0.97]			Teepe 2015	26	14	81	134	Adults	0.24 [0.17, 0.34]	0.91 [0.85, 0.95]			Steketee 1988	60	206	228	738	Adults	0.21 [0.16, 0.26]	0.78 [0.75, 0.81]			Wright 1995	4	149	10	143	Adults	0.29 [0.08, 0.58]	0.49 [0.43, 0.55]			Granstrom 1991	7	15	156	107	Both	0.04 [0.02, 0.09]	0.88 [0.81, 0.93]			Dinu 2014	4	3	27	16	Both	0.13 [0.04, 0.30]	0.84 [0.60, 0.97]			Schlapfer 1995	0	298	4	1103	Both	0.00 [0.00, 0.60]	0.79 [0.76, 0.81]			Stefanoff 2014	8	21	55	113	Both	0.13 [0.06, 0.23]	0.84 [0.77, 0.90]			Castagnini 2010	1	5	32	28	Children	0.03 [0.00, 0.16]	0.85 [0.68, 0.95]			Crowcroft 2003	11	45	14	56	Children	0.44 [0.24, 0.65]	0.55 [0.45, 0.65]			Abu Raya 2013	7	43	16	53	Children	0.30 [0.13, 0.53]	0.55 [0.45, 0.65]			Guinto-Ocampo 2008	1	14	15	89	Children	0.06 [0.00, 0.30]	0.86 [0.78, 0.92]			Del Valle Mendoza 2015	20	28	31	54	Children	0.39 [0.26, 0.54]	0.66 [0.55, 0.76]			Fine 2010	1	86	37	319	Children	0.03 [0.00, 0.14]	0.79 [0.74, 0.83]			Ferronato 2013	3	4	19	8	Children	0.14 [0.03, 0.35]	0.67 [0.35, 0.90]			Nicholai 2013	3	13	16	6	Children	0.16 [0.03, 0.40]	0.32 [0.13, 0.57]			Kayna 2015	41	220	26	162	Children	0.61 [0.49, 0.73]	0.42 [0.37, 0.48]			Nieves 2011	7	58	24	36	Children	0.23 [0.10, 0.41]	0.38 [0.28, 0.49]			van den Brink 2014	26	1045	67	1931	Children	0.28 [0.19, 0.38]	0.65 [0.63, 0.67]			Zouari 2012	361	1059	417	1365	Children	0.46 [0.43, 0.50]	0.56 [0.54, 0.58]			Wymann 2011	6	13	10	46	Children	0.38 [0.15, 0.65]	0.78 [0.65, 0.88]			
Study	TP	FP	FN	TN	Child/Adult	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)																																																																																																																																																																																																																																																																																												
Bonhoeffer 2005	3	5	5	13	Adults	0.38 [0.09, 0.76]	0.72 [0.47, 0.90]																																																																																																																																																																																																																																																																																														
Craig 2007	2	9	8	18	Adults	0.20 [0.03, 0.56]	0.67 [0.46, 0.83]																																																																																																																																																																																																																																																																																														
Karagul 2014	3	77	12	122	Adults	0.20 [0.04, 0.48]	0.61 [0.54, 0.68]																																																																																																																																																																																																																																																																																														
Jackson 2000	10	92	37	180	Adults	0.21 [0.11, 0.36]	0.66 [0.60, 0.72]																																																																																																																																																																																																																																																																																														
Myashita 2013	27	234	156	898	Adults	0.15 [0.10, 0.21]	0.79 [0.77, 0.82]																																																																																																																																																																																																																																																																																														
Koh 2016	5	74	11	222	Adults	0.31 [0.11, 0.59]	0.75 [0.70, 0.80]																																																																																																																																																																																																																																																																																														
Schmitt-Crohe 1995	12	53	62	244	Adults	0.16 [0.09, 0.27]	0.82 [0.77, 0.86]																																																																																																																																																																																																																																																																																														
Park (B) 2014	2	21	32	435	Adults	0.06 [0.01, 0.20]	0.95 [0.93, 0.97]																																																																																																																																																																																																																																																																																														
Teepe 2015	26	14	81	134	Adults	0.24 [0.17, 0.34]	0.91 [0.85, 0.95]																																																																																																																																																																																																																																																																																														
Steketee 1988	60	206	228	738	Adults	0.21 [0.16, 0.26]	0.78 [0.75, 0.81]																																																																																																																																																																																																																																																																																														
Wright 1995	4	149	10	143	Adults	0.29 [0.08, 0.58]	0.49 [0.43, 0.55]																																																																																																																																																																																																																																																																																														
Granstrom 1991	7	15	156	107	Both	0.04 [0.02, 0.09]	0.88 [0.81, 0.93]																																																																																																																																																																																																																																																																																														
Dinu 2014	4	3	27	16	Both	0.13 [0.04, 0.30]	0.84 [0.60, 0.97]																																																																																																																																																																																																																																																																																														
Schlapfer 1995	0	298	4	1103	Both	0.00 [0.00, 0.60]	0.79 [0.76, 0.81]																																																																																																																																																																																																																																																																																														
Stefanoff 2014	8	21	55	113	Both	0.13 [0.06, 0.23]	0.84 [0.77, 0.90]																																																																																																																																																																																																																																																																																														
Castagnini 2010	1	5	32	28	Children	0.03 [0.00, 0.16]	0.85 [0.68, 0.95]																																																																																																																																																																																																																																																																																														
Crowcroft 2003	11	45	14	56	Children	0.44 [0.24, 0.65]	0.55 [0.45, 0.65]																																																																																																																																																																																																																																																																																														
Abu Raya 2013	7	43	16	53	Children	0.30 [0.13, 0.53]	0.55 [0.45, 0.65]																																																																																																																																																																																																																																																																																														
Guinto-Ocampo 2008	1	14	15	89	Children	0.06 [0.00, 0.30]	0.86 [0.78, 0.92]																																																																																																																																																																																																																																																																																														
Del Valle Mendoza 2015	20	28	31	54	Children	0.39 [0.26, 0.54]	0.66 [0.55, 0.76]																																																																																																																																																																																																																																																																																														
Fine 2010	1	86	37	319	Children	0.03 [0.00, 0.14]	0.79 [0.74, 0.83]																																																																																																																																																																																																																																																																																														
Ferronato 2013	3	4	19	8	Children	0.14 [0.03, 0.35]	0.67 [0.35, 0.90]																																																																																																																																																																																																																																																																																														
Nicholai 2013	3	13	16	6	Children	0.16 [0.03, 0.40]	0.32 [0.13, 0.57]																																																																																																																																																																																																																																																																																														
Kayna 2015	41	220	26	162	Children	0.61 [0.49, 0.73]	0.42 [0.37, 0.48]																																																																																																																																																																																																																																																																																														
Nieves 2011	7	58	24	36	Children	0.23 [0.10, 0.41]	0.38 [0.28, 0.49]																																																																																																																																																																																																																																																																																														
van den Brink 2014	26	1045	67	1931	Children	0.28 [0.19, 0.38]	0.65 [0.63, 0.67]																																																																																																																																																																																																																																																																																														
Zouari 2012	361	1059	417	1365	Children	0.46 [0.43, 0.50]	0.56 [0.54, 0.58]																																																																																																																																																																																																																																																																																														
Wymann 2011	6	13	10	46	Children	0.38 [0.15, 0.65]	0.78 [0.65, 0.88]																																																																																																																																																																																																																																																																																														
Headache	Headache(s)	<table border="1"> <thead> <tr> <th>Study</th> <th>TP</th> <th>FP</th> <th>FN</th> <th>TN</th> <th>Child/Adult</th> <th>Sensitivity (95% CI)</th> <th>Specificity (95% CI)</th> <th>Sensitivity (95% CI)</th> <th>Specificity (95% CI)</th> </tr> </thead> <tbody> <tr><td>Siriyakorn 2016</td><td>3</td><td>16</td><td>11</td><td>46</td><td>Adults</td><td>0.21 [0.05, 0.51]</td><td>0.74 [0.62, 0.84]</td><td></td><td></td></tr> <tr><td>Park (B) 2014</td><td>3</td><td>68</td><td>31</td><td>388</td><td>Adults</td><td>0.09 [0.02, 0.24]</td><td>0.85 [0.81, 0.88]</td><td></td><td></td></tr> <tr><td>Jackson 2000</td><td>26</td><td>152</td><td>21</td><td>120</td><td>Adults</td><td>0.55 [0.40, 0.70]</td><td>0.44 [0.38, 0.50]</td><td></td><td></td></tr> <tr><td>Philipson 2013</td><td>14</td><td>144</td><td>9</td><td>55</td><td>Both</td><td>0.61 [0.39, 0.80]</td><td>0.28 [0.22, 0.34]</td><td></td><td></td></tr> <tr><td>Harnden 2006</td><td>29</td><td>63</td><td>35</td><td>44</td><td>Children</td><td>0.45 [0.33, 0.58]</td><td>0.41 [0.32, 0.51]</td><td></td><td></td></tr> </tbody> </table>	Study	TP	FP	FN	TN	Child/Adult	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)	Siriyakorn 2016	3	16	11	46	Adults	0.21 [0.05, 0.51]	0.74 [0.62, 0.84]			Park (B) 2014	3	68	31	388	Adults	0.09 [0.02, 0.24]	0.85 [0.81, 0.88]			Jackson 2000	26	152	21	120	Adults	0.55 [0.40, 0.70]	0.44 [0.38, 0.50]			Philipson 2013	14	144	9	55	Both	0.61 [0.39, 0.80]	0.28 [0.22, 0.34]			Harnden 2006	29	63	35	44	Children	0.45 [0.33, 0.58]	0.41 [0.32, 0.51]																																																																																																																																																																																																																																									
Study	TP	FP	FN	TN	Child/Adult	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)																																																																																																																																																																																																																																																																																												
Siriyakorn 2016	3	16	11	46	Adults	0.21 [0.05, 0.51]	0.74 [0.62, 0.84]																																																																																																																																																																																																																																																																																														
Park (B) 2014	3	68	31	388	Adults	0.09 [0.02, 0.24]	0.85 [0.81, 0.88]																																																																																																																																																																																																																																																																																														
Jackson 2000	26	152	21	120	Adults	0.55 [0.40, 0.70]	0.44 [0.38, 0.50]																																																																																																																																																																																																																																																																																														
Philipson 2013	14	144	9	55	Both	0.61 [0.39, 0.80]	0.28 [0.22, 0.34]																																																																																																																																																																																																																																																																																														
Harnden 2006	29	63	35	44	Children	0.45 [0.33, 0.58]	0.41 [0.32, 0.51]																																																																																																																																																																																																																																																																																														







Clinical characteristic	Described as	Forest plot										SROC plot																															
Myalgia	Myalgia Other muscle pain	<table border="1"> <thead> <tr> <th>Study</th> <th>TP</th> <th>FP</th> <th>FN</th> <th>TN</th> <th>Child/Adult</th> <th>Sensitivity (95% CI)</th> <th>Specificity (95% CI)</th> <th>Sensitivity (95% CI)</th> <th>Specificity (95% CI)</th> </tr> </thead> <tbody> <tr> <td>Jackson 2000</td> <td>2</td> <td>53</td> <td>21</td> <td>146</td> <td>Adults</td> <td>0.09 [0.01, 0.28]</td> <td>0.73 [0.67, 0.79]</td> <td></td> <td></td> </tr> <tr> <td>Park (B) 2014</td> <td>2</td> <td>28</td> <td>32</td> <td>428</td> <td>Adults</td> <td>0.06 [0.01, 0.20]</td> <td>0.94 [0.91, 0.96]</td> <td></td> <td></td> </tr> <tr> <td>Phillipson 2013</td> <td>20</td> <td>125</td> <td>27</td> <td>147</td> <td>Both</td> <td>0.43 [0.28, 0.58]</td> <td>0.54 [0.48, 0.60]</td> <td></td> <td></td> </tr> </tbody> </table>	Study	TP	FP	FN	TN	Child/Adult	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)	Jackson 2000	2	53	21	146	Adults	0.09 [0.01, 0.28]	0.73 [0.67, 0.79]			Park (B) 2014	2	28	32	428	Adults	0.06 [0.01, 0.20]	0.94 [0.91, 0.96]			Phillipson 2013	20	125	27	147	Both	0.43 [0.28, 0.58]	0.54 [0.48, 0.60]			<p>Legend ○ Child/Adult: Adults ◇ Child/Adult: Both</p>
Study	TP	FP	FN	TN	Child/Adult	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)																																		
Jackson 2000	2	53	21	146	Adults	0.09 [0.01, 0.28]	0.73 [0.67, 0.79]																																				
Park (B) 2014	2	28	32	428	Adults	0.06 [0.01, 0.20]	0.94 [0.91, 0.96]																																				
Phillipson 2013	20	125	27	147	Both	0.43 [0.28, 0.58]	0.54 [0.48, 0.60]																																				
Conjunctival changes	Conjunctival haemorrhage Conjunctival injection Conjunctivitis	<table border="1"> <thead> <tr> <th>Study</th> <th>TP</th> <th>FP</th> <th>FN</th> <th>TN</th> <th>Child/Adult</th> <th>Sensitivity (95% CI)</th> <th>Specificity (95% CI)</th> <th>Sensitivity (95% CI)</th> <th>Specificity (95% CI)</th> </tr> </thead> <tbody> <tr> <td>Jackson 2000</td> <td>7</td> <td>24</td> <td>40</td> <td>248</td> <td>Adults</td> <td>0.15 [0.06, 0.28]</td> <td>0.91 [0.87, 0.94]</td> <td></td> <td></td> </tr> <tr> <td>Kayina 2015</td> <td>3</td> <td>15</td> <td>64</td> <td>367</td> <td>Children</td> <td>0.04 [0.01, 0.13]</td> <td>0.96 [0.94, 0.98]</td> <td></td> <td></td> </tr> <tr> <td>Crowcroft 2003</td> <td>1</td> <td>3</td> <td>24</td> <td>98</td> <td>Children</td> <td>0.04 [0.00, 0.20]</td> <td>0.97 [0.92, 0.99]</td> <td></td> <td></td> </tr> </tbody> </table>	Study	TP	FP	FN	TN	Child/Adult	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)	Jackson 2000	7	24	40	248	Adults	0.15 [0.06, 0.28]	0.91 [0.87, 0.94]			Kayina 2015	3	15	64	367	Children	0.04 [0.01, 0.13]	0.96 [0.94, 0.98]			Crowcroft 2003	1	3	24	98	Children	0.04 [0.00, 0.20]	0.97 [0.92, 0.99]			<p>Legend ○ Child/Adult: Adults ◇ Child/Adult: Children</p>
Study	TP	FP	FN	TN	Child/Adult	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)																																		
Jackson 2000	7	24	40	248	Adults	0.15 [0.06, 0.28]	0.91 [0.87, 0.94]																																				
Kayina 2015	3	15	64	367	Children	0.04 [0.01, 0.13]	0.96 [0.94, 0.98]																																				
Crowcroft 2003	1	3	24	98	Children	0.04 [0.00, 0.20]	0.97 [0.92, 0.99]																																				


Clinical characteristic	Described as	Forest plot										SROC plot																															
White blood cell count	WCC > 10000 cells/ml Leukocytosis (>=15000/uL WBC >= 16,000 cell/ml)	<table border="1"> <thead> <tr> <th>Study</th> <th>TP</th> <th>FP</th> <th>FN</th> <th>TN</th> <th>Child/Adult</th> <th>Sensitivity (95% CI)</th> <th>Specificity (95% CI)</th> <th>Sensitivity (95% CI)</th> <th>Specificity (95% CI)</th> </tr> </thead> <tbody> <tr> <td>Jackson 2000</td> <td>6</td> <td>35</td> <td>41</td> <td>237</td> <td>Adults</td> <td>0.13 [0.05, 0.26]</td> <td>0.87 [0.83, 0.91]</td> <td></td> <td></td> </tr> <tr> <td>Zouari 2012</td> <td>84</td> <td>144</td> <td>36</td> <td>335</td> <td>Children</td> <td>0.70 [0.61, 0.78]</td> <td>0.70 [0.66, 0.74]</td> <td></td> <td></td> </tr> <tr> <td>Shojaei 2014</td> <td>13</td> <td>39</td> <td>6</td> <td>60</td> <td>Children</td> <td>0.68 [0.43, 0.87]</td> <td>0.61 [0.50, 0.70]</td> <td></td> <td></td> </tr> </tbody> </table>	Study	TP	FP	FN	TN	Child/Adult	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)	Jackson 2000	6	35	41	237	Adults	0.13 [0.05, 0.26]	0.87 [0.83, 0.91]			Zouari 2012	84	144	36	335	Children	0.70 [0.61, 0.78]	0.70 [0.66, 0.74]			Shojaei 2014	13	39	6	60	Children	0.68 [0.43, 0.87]	0.61 [0.50, 0.70]			<p>Legend Child/Adult: Adults Child/Adult: Children</p>
Study	TP	FP	FN	TN	Child/Adult	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)																																		
Jackson 2000	6	35	41	237	Adults	0.13 [0.05, 0.26]	0.87 [0.83, 0.91]																																				
Zouari 2012	84	144	36	335	Children	0.70 [0.61, 0.78]	0.70 [0.66, 0.74]																																				
Shojaei 2014	13	39	6	60	Children	0.68 [0.43, 0.87]	0.61 [0.50, 0.70]																																				
Fatigue	Malaise Tiredness	<table border="1"> <thead> <tr> <th>Study</th> <th>TP</th> <th>FP</th> <th>FN</th> <th>TN</th> <th>Child/Adult</th> <th>Sensitivity (95% CI)</th> <th>Specificity (95% CI)</th> <th>Sensitivity (95% CI)</th> <th>Specificity (95% CI)</th> </tr> </thead> <tbody> <tr> <td>Park (B) 2014</td> <td>2</td> <td>14</td> <td>32</td> <td>442</td> <td>Adults</td> <td>0.06 [0.01, 0.20]</td> <td>0.97 [0.95, 0.98]</td> <td></td> <td></td> </tr> <tr> <td>Phillipson 2013</td> <td>1</td> <td>15</td> <td>22</td> <td>184</td> <td>Both</td> <td>0.04 [0.00, 0.22]</td> <td>0.92 [0.88, 0.96]</td> <td></td> <td></td> </tr> </tbody> </table>	Study	TP	FP	FN	TN	Child/Adult	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)	Park (B) 2014	2	14	32	442	Adults	0.06 [0.01, 0.20]	0.97 [0.95, 0.98]			Phillipson 2013	1	15	22	184	Both	0.04 [0.00, 0.22]	0.92 [0.88, 0.96]			<p>Legend Child/Adult: Adults Child/Adult: Both</p>										
Study	TP	FP	FN	TN	Child/Adult	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)																																		
Park (B) 2014	2	14	32	442	Adults	0.06 [0.01, 0.20]	0.97 [0.95, 0.98]																																				
Phillipson 2013	1	15	22	184	Both	0.04 [0.00, 0.22]	0.92 [0.88, 0.96]																																				

Clinical characteristic	Described as	Forest plot	SROC plot																														
Sweating	Sweating	<table border="1"> <thead> <tr> <th>Study</th> <th>TP</th> <th>FP</th> <th>FN</th> <th>TN</th> <th>Child/Adult</th> <th>Sensitivity (95% CI)</th> <th>Specificity (95% CI)</th> <th>Sensitivity (95% CI)</th> <th>Specificity (95% CI)</th> </tr> </thead> <tbody> <tr> <td>Phillipson 2013</td> <td>15</td> <td>113</td> <td>8</td> <td>86</td> <td>Both</td> <td>0.65 [0.43, 0.84]</td> <td>0.43 [0.36, 0.50]</td> <td></td> <td></td> </tr> <tr> <td>Hamden 2006</td> <td>24</td> <td>56</td> <td>39</td> <td>52</td> <td>Children</td> <td>0.38 [0.26, 0.51]</td> <td>0.48 [0.38, 0.58]</td> <td></td> <td></td> </tr> </tbody> </table>	Study	TP	FP	FN	TN	Child/Adult	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)	Phillipson 2013	15	113	8	86	Both	0.65 [0.43, 0.84]	0.43 [0.36, 0.50]			Hamden 2006	24	56	39	52	Children	0.38 [0.26, 0.51]	0.48 [0.38, 0.58]			<p>Legend</p> <ul style="list-style-type: none"> ○ Child/Adult: Children ◇ Child/Adult: Both
Study	TP	FP	FN	TN	Child/Adult	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)																								
Phillipson 2013	15	113	8	86	Both	0.65 [0.43, 0.84]	0.43 [0.36, 0.50]																										
Hamden 2006	24	56	39	52	Children	0.38 [0.26, 0.51]	0.48 [0.38, 0.58]																										
Seizure	History of seizure Convulsions	<table border="1"> <thead> <tr> <th>Study</th> <th>TP</th> <th>FP</th> <th>FN</th> <th>TN</th> <th>Child/Adult</th> <th>Sensitivity (95% CI)</th> <th>Specificity (95% CI)</th> <th>Sensitivity (95% CI)</th> <th>Specificity (95% CI)</th> </tr> </thead> <tbody> <tr> <td>Greenberg 2007</td> <td>1</td> <td>0</td> <td>10</td> <td>63</td> <td>Children</td> <td>0.09 [0.00, 0.41]</td> <td>1.00 [0.94, 1.00]</td> <td></td> <td></td> </tr> <tr> <td>Fine 2010</td> <td>0</td> <td>4</td> <td>38</td> <td>401</td> <td>Children</td> <td>0.00 [0.00, 0.09]</td> <td>0.99 [0.97, 1.00]</td> <td></td> <td></td> </tr> </tbody> </table>	Study	TP	FP	FN	TN	Child/Adult	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)	Greenberg 2007	1	0	10	63	Children	0.09 [0.00, 0.41]	1.00 [0.94, 1.00]			Fine 2010	0	4	38	401	Children	0.00 [0.00, 0.09]	0.99 [0.97, 1.00]			<p>Legend</p> <ul style="list-style-type: none"> ○ Child/Adult: Children
Study	TP	FP	FN	TN	Child/Adult	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)																								
Greenberg 2007	1	0	10	63	Children	0.09 [0.00, 0.41]	1.00 [0.94, 1.00]																										
Fine 2010	0	4	38	401	Children	0.00 [0.00, 0.09]	0.99 [0.97, 1.00]																										





CLINICAL JUDGEMENT





PATIENT DEMOGRAPHICS





Clinical characteristic	Described as	Forest plot										SROC plot																																																			
Smoking	Current smoker Smoker in household	<table border="1"> <thead> <tr> <th>Study</th> <th>TP</th> <th>FP</th> <th>FN</th> <th>TN</th> <th>Child/Adult</th> <th>Sensitivity (95% CI)</th> <th>Specificity (95% CI)</th> <th>Sensitivity (95% CI)</th> <th>Specificity (95% CI)</th> </tr> </thead> <tbody> <tr> <td>Craig 2007</td> <td>1</td> <td>3</td> <td>9</td> <td>24</td> <td>Adults</td> <td>0.10 [0.00, 0.45]</td> <td>0.89 [0.71, 0.98]</td> <td></td> <td></td> </tr> <tr> <td>Wright 1995</td> <td>4</td> <td>20</td> <td>12</td> <td>39</td> <td>Adults</td> <td>0.25 [0.07, 0.52]</td> <td>0.66 [0.53, 0.78]</td> <td></td> <td></td> </tr> <tr> <td>Teepe 2015</td> <td>25</td> <td>835</td> <td>67</td> <td>2144</td> <td>Adults</td> <td>0.27 [0.18, 0.37]</td> <td>0.72 [0.70, 0.74]</td> <td></td> <td></td> </tr> <tr> <td>Stefanoff 2014</td> <td>65</td> <td>166</td> <td>223</td> <td>778</td> <td>Both</td> <td>0.23 [0.18, 0.28]</td> <td>0.82 [0.80, 0.85]</td> <td></td> <td></td> </tr> <tr> <td>Harnden 2006</td> <td>20</td> <td>42</td> <td>43</td> <td>58</td> <td>Children</td> <td>0.32 [0.21, 0.45]</td> <td>0.58 [0.48, 0.68]</td> <td></td> <td></td> </tr> </tbody> </table>	Study	TP	FP	FN	TN	Child/Adult	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)	Craig 2007	1	3	9	24	Adults	0.10 [0.00, 0.45]	0.89 [0.71, 0.98]			Wright 1995	4	20	12	39	Adults	0.25 [0.07, 0.52]	0.66 [0.53, 0.78]			Teepe 2015	25	835	67	2144	Adults	0.27 [0.18, 0.37]	0.72 [0.70, 0.74]			Stefanoff 2014	65	166	223	778	Both	0.23 [0.18, 0.28]	0.82 [0.80, 0.85]			Harnden 2006	20	42	43	58	Children	0.32 [0.21, 0.45]	0.58 [0.48, 0.68]			<p>Legend</p> <ul style="list-style-type: none"> ○ Child/Adult: Adults ◇ Child/Adult: Children □ Child/Adult: Both
Study	TP	FP	FN	TN	Child/Adult	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)																																																						
Craig 2007	1	3	9	24	Adults	0.10 [0.00, 0.45]	0.89 [0.71, 0.98]																																																								
Wright 1995	4	20	12	39	Adults	0.25 [0.07, 0.52]	0.66 [0.53, 0.78]																																																								
Teepe 2015	25	835	67	2144	Adults	0.27 [0.18, 0.37]	0.72 [0.70, 0.74]																																																								
Stefanoff 2014	65	166	223	778	Both	0.23 [0.18, 0.28]	0.82 [0.80, 0.85]																																																								
Harnden 2006	20	42	43	58	Children	0.32 [0.21, 0.45]	0.58 [0.48, 0.68]																																																								
Previous whooping cough	Whooping cough history Previous similar cough Previous (diagnosis of) pertussis	<table border="1"> <thead> <tr> <th>Study</th> <th>TP</th> <th>FP</th> <th>FN</th> <th>TN</th> <th>Child/Adult</th> <th>Sensitivity (95% CI)</th> <th>Specificity (95% CI)</th> <th>Sensitivity (95% CI)</th> <th>Specificity (95% CI)</th> </tr> </thead> <tbody> <tr> <td>Senzilet 2001</td> <td>5</td> <td>29</td> <td>83</td> <td>325</td> <td>Adults</td> <td>0.06 [0.02, 0.13]</td> <td>0.92 [0.88, 0.94]</td> <td></td> <td></td> </tr> <tr> <td>Bonhoeffer 2005</td> <td>7</td> <td>13</td> <td>1</td> <td>5</td> <td>Adults</td> <td>0.88 [0.47, 1.00]</td> <td>0.28 [0.10, 0.53]</td> <td></td> <td></td> </tr> <tr> <td>Gilberg 2002</td> <td>16</td> <td>5</td> <td>32</td> <td>24</td> <td>Adults</td> <td>0.33 [0.20, 0.48]</td> <td>0.83 [0.64, 0.94]</td> <td></td> <td></td> </tr> <tr> <td>Schmitt-Grohe 1995</td> <td>13</td> <td>35</td> <td>38</td> <td>84</td> <td>Adults</td> <td>0.25 [0.14, 0.40]</td> <td>0.71 [0.62, 0.79]</td> <td></td> <td></td> </tr> </tbody> </table>	Study	TP	FP	FN	TN	Child/Adult	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)	Senzilet 2001	5	29	83	325	Adults	0.06 [0.02, 0.13]	0.92 [0.88, 0.94]			Bonhoeffer 2005	7	13	1	5	Adults	0.88 [0.47, 1.00]	0.28 [0.10, 0.53]			Gilberg 2002	16	5	32	24	Adults	0.33 [0.20, 0.48]	0.83 [0.64, 0.94]			Schmitt-Grohe 1995	13	35	38	84	Adults	0.25 [0.14, 0.40]	0.71 [0.62, 0.79]			<p>Legend</p> <ul style="list-style-type: none"> ○ Child/Adult: Adults 										
Study	TP	FP	FN	TN	Child/Adult	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)																																																						
Senzilet 2001	5	29	83	325	Adults	0.06 [0.02, 0.13]	0.92 [0.88, 0.94]																																																								
Bonhoeffer 2005	7	13	1	5	Adults	0.88 [0.47, 1.00]	0.28 [0.10, 0.53]																																																								
Gilberg 2002	16	5	32	24	Adults	0.33 [0.20, 0.48]	0.83 [0.64, 0.94]																																																								
Schmitt-Grohe 1995	13	35	38	84	Adults	0.25 [0.14, 0.40]	0.71 [0.62, 0.79]																																																								